<html lang="en" class="pb-page js" data-request-id="94d6763b1396f211-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6763b1396f211-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/m_sAQpMSdEO-CXDdDRagXmUjt1FPs-yyMLs8phLM1sG2sUzAq9MjIPQLFQNsOR2ZlXe03mhI5R9oe8ln7kVX-A=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6763b1396f211-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.3402378010456999"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Rheumatoid Arthritis|Psoriasis">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Rheumatology|Dermatology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2022516","title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","category":"Research","type":"Original Article","topics":"Rheumatoid Arthritis|Psoriasis","specialties":"Rheumatology|Dermatology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-04-01T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Rheumatoid Arthritis|Psoriasis\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Rheumatology|Dermatology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2022516","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","doi":"10.1056/NEJMdo005993","issueDate":"2021-04-01T00:00Z","age":"6Months-1990","isFree":"y","topics":"Rheumatoid Arthritis|Psoriasis","viewType":"Full","specialties":"Rheumatology|Dermatology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6763b1396f211-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis"><meta name="dc.Creator" content="Iain B. McInnes"><meta name="dc.Creator" content="Jaclyn K. Anderson"><meta name="dc.Creator" content="Marina Magrey"><meta name="dc.Creator" content="Joseph F. Merola"><meta name="dc.Creator" content="Yi Liu"><meta name="dc.Creator" content="Mitsumasa Kishimoto"><meta name="dc.Creator" content="Slawomir Jeka"><meta name="dc.Creator" content="Cesar Pacheco-Tena"><meta name="dc.Creator" content="Xin Wang"><meta name="dc.Creator" content="Liang Chen"><meta name="dc.Creator" content="Patrick Zueger"><meta name="dc.Creator" content="John Liu"><meta name="dc.Creator" content="Aileen L. Pangan"><meta name="dc.Creator" content="Frank Behrens"><meta name="dc.Description" content="The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, i..."><meta name="Description" content="The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, i..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-04-01"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2022516"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202104013841308"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2022516">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2022516">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2022516">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis | NEJM">
        <meta property="og:title" content="Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2022516">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/478506ca-9706-427f-9dc8-3e91b611d73c/nejmoa2022516_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/478506ca-9706-427f-9dc8-3e91b611d73c/nejmoa2022516_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis.
The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis
factor α inhibitor, i...">
        <meta name="twitter:description" content="The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis.
The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis
factor α inhibitor, i...">
    


    
    
        <meta property="og:image:width" content="1644">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2022516">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022516">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.384.issue-13;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2022516;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2022516" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2022516" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2022516" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2022516" class="inputDoi"><input type="hidden" value="I.B. McInnes and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1227-1239" class="inputCitation"><input type="hidden" value="03-31-2021" class="inputEPubDate"><input type="hidden" value="April 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6763b1396f211-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Iain B.</span> <span property="familyName">McInnes</span>, <span property="honorificSuffix">F.R.C.P.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jaclyn K.</span> <span property="familyName">Anderson</span>, <span property="honorificSuffix">D.O.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marina</span> <span property="familyName">Magrey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joseph F.</span> <span property="familyName">Merola</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yi</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mitsumasa</span> <span property="familyName">Kishimoto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Slawomir</span> <span property="familyName">Jeka</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+6</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cesar</span> <span property="familyName">Pacheco-Tena</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xin</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Liang</span> <span property="familyName">Chen</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patrick</span> <span property="familyName">Zueger</span>, <span property="honorificSuffix">Pharm.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Aileen L.</span> <span property="familyName">Pangan</span>, <span property="honorificSuffix">M.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Frank</span> <span property="familyName">Behrens</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-6</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 31, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1227</span>-<span property="pageEnd">1239</span></div><div class="doi">DOI: 10.1056/NEJMoa2022516</div><div class="core-enumeration"><a href="/toc/nejm/384/13"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">13</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DIain%2BB.%2BMcInnes%252C%2BJaclyn%2BK.%2BAnderson%252C%2BMarina%2BMagrey%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2022516%26title%3DTrial%2Bof%2BUpadacitinib%2Band%2BAdalimumab%2Bfor%2BPsoriatic%2BArthritis%26publicationDate%3D04%252F01%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2022516" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DIain%2BB.%2BMcInnes%252C%2BJaclyn%2BK.%2BAnderson%252C%2BMarina%2BMagrey%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D13%26contentID%3D10.1056%252FNEJMoa2022516%26title%3DTrial%2Bof%2BUpadacitinib%2Band%2BAdalimumab%2Bfor%2BPsoriatic%2BArthritis%26publicationDate%3D04%252F01%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/64cd4c6f-6ccc-4486-90a2-59883da686ba/nejmoa2022516.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2022516.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022516" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2022516" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2022516.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">In a 24-week, phase 3 trial, we randomly assigned patients in a 1:1:1:1 ratio to receive oral upadacitinib at a dose of 15 mg or 30 mg once daily, placebo, or subcutaneous adalimumab (40 mg every other week).</span> The primary end point was an American College of Rheumatology 20 (ACR20) response (≥20% decrease in the number of tender and swollen joints and ≥20% improvement in at least three of five other domains) at week 12 with upadacitinib as compared with placebo. Secondary end points included comparisons of upadacitinib with adalimumab.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 1704 patients received an active drug or placebo. <span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The percentage of patients who had an ACR20 response at week 12 was 70.6% with 15-mg upadacitinib, 78.5% with 30-mg upadacitinib, 36.2% with placebo (P&lt;0.001 for both upadacitinib doses vs. placebo), and 65.0% with adalimumab.</span> The difference between groups for 15-mg upadacitinib as compared with adalimumab was 5.6 percentage points (95% confidence interval [CI], −0.6 to 11.8) and for 30-mg upadacitinib as compared with adalimumab was 13.5 percentage points (95% CI, 7.5 to 19.4). Both upadacitinib doses were noninferior to adalimumab for the ACR20 response at week 12; the 30-mg dose but not the 15-mg dose was superior to adalimumab. The incidence of adverse events through week 24 was 66.9% with 15-mg upadacitinib, 72.3% with 30-mg upadacitinib, 59.6% with placebo, and 64.8% with adalimumab. There were serious infections in 1.2%, 2.6%, 0.9%, and 0.7% of the patients, respectively. Hepatic disorders occurred in 9.1% of patients in the 15-mg upadacitinib group and 12.3% in the 30-mg upadacitinib group, but grade 3 increases in aminotransferase levels occurred in 2% of patients or fewer in all groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">The percentage of patients with psoriatic arthritis who had an ACR20 response at week 12 was significantly higher with 15-mg or 30-mg upadacitinib than with placebo. The 30-mg dose but not the 15-mg dose was superior to adalimumab. Adverse events were more frequent with upadacitinib than with placebo. (Funded by AbbVie; SELECT-PsA 1 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03104400" target="_blank">NCT03104400</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005993/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005993" data-multimedia-filename="NEJMdo005993_600x400.jpg">
                <img src="/cms/asset/72960074-723b-423a-b125-95e1f5f48b06/media/NEJMdo005993_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005993" data-multimedia-filename="NEJMdo005993_600x400.jpg">Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Upadacitinib is an oral, reversible Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5" id="body-ref-r5-1" href-manipulated="true">1-5</a></sup> Adalimumab is a tumor necrosis factor α inhibitor used to treat rheumatoid arthritis and psoriatic arthritis. In one trial involving patients with rheumatoid arthritis, upadacitinib at a dose of 15 mg once daily was superior to adalimumab at week 12 in the percentage of patients who had at least 50% improvement according to the American College of Rheumatology (ACR) criteria and in the percentage of patients who had a score of 3.2 or less on the Disease Activity Score for 28 joints (range, 0 to 9.4, with higher scores indicating more disease activity).<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> We conducted SELECT-PsA 1, a double-blind, phase 3 trial comparing upadacitinib with placebo and with adalimumab as an active comparator in patients with psoriatic arthritis who had an inadequate response or unacceptable side effects with nonbiologic disease-modifying antirheumatic drugs (DMARDs).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients were 18 years of age or older, had received a diagnosis of psoriatic arthritis, fulfilled the Classification Criteria for Psoriatic Arthritis,<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> and had historical or current plaque psoriasis. All the patients had at least 3 swollen joints (of 66 tested) and at least 3 tender joints (of 68 tested) at baseline, the presence at screening of one or more erosions on the hands or feet on radiography (as determined by central imaging review) or a high-sensitivity C-reactive protein level that was greater than the laboratory-defined upper limit of the normal range, and an inadequate response or unacceptable side effects with at least one nonbiologic DMARD. Stable treatment with nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, and no more than two nonbiologic DMARDs was permitted but not required. Patients were excluded if they had previous exposure to biologic therapies or JAK inhibitors. Details regarding inclusion and exclusion criteria are provided in Section S2 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">The trial was conducted at 281 sites in 45 countries and was initiated in April 2017; the last patient completed week 24 in December 2019 (Table S1 in the <a href="#ap2">Supplementary Appendix</a>). Results for efficacy and safety are presented through week 24 (with the primary end point at week 12). The extension period is ongoing, with up to 3 years of total anticipated trial participation (Fig. S1).</div><div role="paragraph">Patients were randomly assigned by means of an interactive-response system in a 1:1:1:1 ratio to receive oral upadacitinib at a dose of either 15 mg or 30 mg once daily, placebo followed by upadacitinib at a dose of 15 mg or 30 mg once daily (1:1 ratio) starting at week 24, or subcutaneous adalimumab at a dose of 40 mg every other week. Randomization was stratified according to the extent of psoriasis (≥3% vs. &lt;3% of body-surface area), current use or nonuse of at least one nonbiologic DMARD, the presence or absence of dactylitis, and the presence or absence of enthesitis.</div><div role="paragraph">Starting at week 16, patients who did not have at least 20% improvement in tender and swollen joint counts as compared with baseline at weeks 12 and 16 could initiate background treatment with DMARDs, NSAIDs, acetaminophen, low-potency opioids, or glucocorticoids or adjust the dose if they were already receiving the drug. During the 24-week placebo-controlled period, investigators, patients, and the sponsor were unaware of the trial group assignments.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted according to the International Council for Harmonisation guidelines and the principles of the Declaration of Helsinki. All the patients provided written informed consent. The trial <a href="#ap1">protocol</a>, available at NEJM.org, was approved by an independent ethics committee or institutional review board at each site.</div><div role="paragraph">The trial was sponsored by AbbVie, which provided upadacitinib, adalimumab, and placebo. Representatives of AbbVie designed the trial, participated in the collection and interpretation of the data, and paid for professional writing assistance, in addition to managing the data collection, maintaining the trial database, and performing the statistical analysis. Confidentiality agreements were in place between the authors and AbbVie. Data were collected by the investigators, their teams, and AbbVie. All the authors contributed to the development of the manuscript with the assistance of a professional medical writer, including interpretation of the data, and approved the final draft for submission. The authors vouch for the completeness and accuracy of the data, for the fidelity of the trial to the protocol, and for the accurate reporting of adverse events.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The primary end point was at least 20% improvement according to the ACR criteria (ACR20 response) with upadacitinib as compared with placebo at week 12. This end point represents a decrease from baseline of at least 20% in the number of tender and swollen joints and an improvement of at least 20% in at least three of five other domains (an assessment of disease activity on a numerical rating scale by both the patient and the physician, an assessment of disability level based on a patient questionnaire, the patient’s assessment of pain on a numerical rating scale, and high-sensitivity C-reactive protein level).</span></div><div role="paragraph">There were 14 multiplicity-controlled secondary end points: the change from baseline in the Health Assessment Questionnaire–Disability Index (HAQ-DI) score (ranging from 0 to 3, with higher scores indicating greater disability) at week 12<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup>; the percentage of patients with a score of 0 or 1 and at least a 2-point decrease from baseline on the Static Investigator Global Assessment (sIGA) of Psoriasis (ranging from 0 to 4, with higher scores indicating more severe skin involvement) at week 16,<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> which was assessed in patients who had a baseline score of at least 2; the percentage of patients with a decrease from baseline of at least 75% in the score on the Psoriasis Area and Severity Index (PASI; ranging from 0 to 72, with higher scores indicating more severe disease) (PASI75 response) at week 16,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> which was assessed in patients who had an affected body-surface of at least 3% at baseline; the change from baseline in the modified total Sharp–van der Heijde Score (ranging from 0 to 528, with higher scores indicating greater damage) at week 24; the percentage of patients with minimal disease activity (determined by fulfilling five of seven criteria: a tender-joint count of ≤1; a swollen-joint count of ≤1; a PASI score of ≤1 or an affected body-surface area of ≤3%; a score on the patient’s assessment of pain of ≤1.5 [ranging from 0 to 10, with higher scores indicating more pain]; a score on the patient’s global assessment of disease activity of ≤2 [ranging from 0 to 10, with higher scores indicating more disease activity]; a HAQ-DI score of ≤0.5; and a score on the Leeds Enthesitis Index [LEI] of ≤1 [ranging from 0 to 6, with higher scores indicating more affected sites]) at week 24<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup>; the percentage of patients with resolution of enthesitis (LEI score, 0) at week 24,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> which was assessed in patients with a baseline LEI score greater than 0; noninferiority of upadacitinib to adalimumab for the ACR20 response at week 12; the change from baseline in the score on the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS; norm-based scores were used, with higher scores indicating better health-related quality of life) at week 12<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup>; the change from baseline in the score on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue; ranging from 0 to 52, with higher scores indicating less fatigue) at week 12<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup>; superiority of upadacitinib to adalimumab for the ACR20 response at week 12; the percentage of patients with resolution of dactylitis (score of 0 on the Leeds Dactylitis Index [LDI; higher scores indicate more affected sites]) at week 24,<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> which was assessed in patients with a baseline LDI score greater than 0; superiority of upadacitinib to adalimumab for the change from baseline in the patient’s assessment of pain (see above) at week 12; superiority of upadacitinib to adalimumab for the change from baseline in the HAQ-DI score at week 12; and the change from baseline in the score on the Self-Assessment of Psoriasis Symptoms (ranging from 0 to 110, with higher scores indicating greater severity of symptoms) at week 16.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> Additional end points, which were not adjusted for multiplicity, are shown in Table S2. The comparisons of upadacitinib with placebo and with adalimumab that are included here were prespecified.</div><div role="paragraph">Changes were made to the protocol and statistical analysis plan during the conduct of the trial to address regulatory-agency feedback regarding the method for noninferiority testing for upadacitinib as compared with adalimumab and for ordering of multiplicity-controlled end points on the basis of data from other trials. All changes were made before the database lock and unmasking of data. The primary and secondary end points were not altered, with the exception of revision of change from baseline in enthesitis to resolution of enthesitis and change from baseline in dactylitis to resolution of dactylitis, removal of the Hochberg test to adjust for multiple comparisons, and revision of the ordering of change in the FACIT-Fatigue score and resolution of dactylitis. Amendments are provided in Section S3 in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Safety</h3><div role="paragraph">Adverse event reporting and clinical laboratory testing were performed by investigators who were unaware of the trial group assignments, and safety results are reported through week 24. An independent, external cardiovascular adjudication committee, whose members were unaware of the trial group assignments, adjudicated deaths and cardiovascular events using prespecified definitions.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">Efficacy analyses were conducted in the modified intention-to-treat population, which included all the patients who had undergone randomization and had received at least one dose of upadacitinib, placebo, or adalimumab. A sample size of 1640 patients was planned to provide at least 90% power to detect a difference between upadacitinib and placebo for the primary end point and for most key secondary end points and at least 85% power for evaluating the noninferiority and superiority of each upadacitinib dose as compared with adalimumab with respect to the ACR20 response at week 12. The trial was not powered to compare upadacitinib with adalimumab regarding the change from baseline in pain and in the HAQ-DI score. All power and sample-size calculations were performed at a two-sided significance level of 0.025, with a dropout rate of 10% taken into account.</div><div role="paragraph">The overall type I error rate for the calculations of the primary end point and the 14 ranked secondary end points was controlled with the use of a two-part sequential graphical multiple-testing procedure. Part 1 started with the primary end point, with the use of α÷2 (α was 0.0499) for each dose followed by a prespecified hierarchical α transfer path that included downstream transfer along the end-point sequence within each dose as well as cross-dose transfer between each upadacitinib dose (Fig. S2). Part 2 was tested only if the results for all end points for both doses in Part 1 were significant. If the results for some end points in Part 1 were not significant, then no α was passed to part 2 of the analysis. The end points in part 2 were tested with the use of level α in a fixed sequence. Once the results for an end point were deemed to be significant, its significance level was transferred to subsequent end points following the prespecified order. When the hierarchical analysis failed, subsequent end points were not tested and only point estimates with multiplicity-unadjusted 95% confidence intervals are given.</div><div role="paragraph">For binary end points, trial groups were compared with the use of the Cochran–Mantel–Haenszel test, with adjustment for current DMARD use for each upadacitinib dose as compared with placebo. Imputation of nonresponse was used for the handling of missing data. Between-group differences in the percentage of patients with a response and the associated 95% confidence intervals with the use of normal approximation for the between-group difference are presented. For the percentage of patients with an ACR20 response at week 12, the noninferiority of each upadacitinib dose to adalimumab was assessed with the use of Koch’s three-group approach; noninferiority was achieved if upadacitinib preserved at least 50% of the placebo-subtracted adalimumab effect. Additional details are provided in Section S4 in the <a href="#ap2">Supplementary Appendix</a>. The original plan for noninferiority comparison of upadacitinib with adalimumab for the ACR20 response at week 12 used a margin of 15 percentage points, and this analysis is also presented.</div><div role="paragraph">For nonradiographic continuous end points, analyses were conducted with the use of a mixed-effects model for repeated measures (MMRM) with fixed effects of treatment, visit, treatment-by-visit interaction, current DMARD use (yes vs. no), and the corresponding baseline value as a covariate. Missing data were handled by means of MMRM, with the assumption of missing data at random. Least-squares mean differences and the associated 95% confidence intervals are provided with the use of MMRM. Prespecified sensitivity analyses that used the tipping-point method were performed for the change from baseline in the HAQ-DI score. Post hoc sensitivity analyses were performed for the SF-36 PCS and FACIT-Fatigue scores (Table S3). The confidence intervals for differences between groups for additional secondary end points and sensitivity analyses were not adjusted for multiplicity, and no clinical inferences can be drawn from those data. Additional details are provided in the statistical analysis plan, available with the protocol at NEJM.org.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Of the 1705 patients who underwent randomization, 1704 received at least one dose of an active drug or placebo (429 received the 15-mg dose of upadacitinib, 423 received the 30-mg dose of upadacitinib, 423 received placebo, and 429 received adalimumab) (Fig. S3). Overall, 1548 patients (90.8%) completed week 24 while receiving upadacitinib, placebo, or adalimumab. The demographic and clinical characteristics of the patients at baseline were similar across groups (<a href="#t1">Table 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t1.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/3db7b1ed-9f0a-4567-8e5b-b362649782a2/assets/images/large/nejmoa2022516_t1.jpg" height="2523" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">238 (55.5)</td><td class="xxxx-borders shading">236 (55.8)</td><td class="xxxx-borders shading">211 (49.9)</td><td class="xxxr-borders shading">222 (51.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age — yr</td><td class="xxxx-borders">51.6±12.2</td><td class="xxxx-borders">49.9±12.4</td><td class="xxxx-borders">50.4±12.2</td><td class="xxxr-borders">51.4±12.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">White race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">386 (90.0)</td><td class="xxxx-borders shading">377 (89.1)</td><td class="xxxx-borders shading">377 (89.1)</td><td class="xxxr-borders shading">375 (87.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Body-mass index ≥25 — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">342 (79.7)</td><td class="xxxx-borders">319 (75.4)</td><td class="xxxx-borders">329 (77.8)</td><td class="xxxr-borders">334 (77.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of psoriatic arthritis — yr</td><td class="xxxx-borders shading">6.2±7.4</td><td class="xxxx-borders shading">5.9±6.4</td><td class="xxxx-borders shading">6.2±7.0</td><td class="xxxr-borders shading">5.9±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any nonbiologic DMARD at baseline — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">353 (82.3)</td><td class="xxxx-borders">346 (81.8)</td><td class="xxxx-borders">347 (82.0)</td><td class="xxxr-borders">347 (80.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Methotrexate alone</td><td class="xxxx-borders shading">279 (65.0)</td><td class="xxxx-borders shading">268 (63.4)</td><td class="xxxx-borders shading">267 (63.1)</td><td class="xxxr-borders shading">270 (62.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Methotrexate + another nonbiologic DMARD</td><td class="xxxx-borders">20 (4.7)</td><td class="xxxx-borders">27 (6.4)</td><td class="xxxx-borders">26 (6.1)</td><td class="xxxr-borders">16 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonbiologic DMARD other than methotrexate</td><td class="xxxx-borders shading">54 (12.6)</td><td class="xxxx-borders shading">51 (12.1)</td><td class="xxxx-borders shading">54 (12.8)</td><td class="xxxr-borders shading">61 (14.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Glucocorticoid use at baseline — no. (%)</td><td class="xxxx-borders">73 (17.0)</td><td class="xxxx-borders">71 (16.8)</td><td class="xxxx-borders">70 (16.5)</td><td class="xxxr-borders">72 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Tender-joint count of 68 joints</td><td class="xxxx-borders shading">20.4±14.7</td><td class="xxxx-borders shading">19.4±13.3</td><td class="xxxx-borders shading">20.0±14.3</td><td class="xxxr-borders shading">20.1±13.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Swollen-joint count of 66 joints</td><td class="xxxx-borders">11.6±9.3</td><td class="xxxx-borders">10.6±7.1</td><td class="xxxx-borders">11.0±8.2</td><td class="xxxr-borders">11.6±8.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">High-sensitivity C-reactive protein &gt;ULN — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">324 (75.5)</td><td class="xxxx-borders shading">324 (76.6)</td><td class="xxxx-borders shading">324 (76.6)</td><td class="xxxr-borders shading">308 (71.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">HAQ-DI score<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">1.2±0.7</td><td class="xxxx-borders">1.1±0.6</td><td class="xxxx-borders">1.1±0.6</td><td class="xxxr-borders">1.1±0.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score for patient’s assessment of pain<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">6.2±2.1</td><td class="xxxx-borders shading">5.9±2.1</td><td class="xxxx-borders shading">6.1±2.1</td><td class="xxxr-borders shading">6.0±2.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Affected body-surface area ≥3% — no. (%)</td><td class="xxxx-borders">214 (49.9)</td><td class="xxxx-borders">210 (49.6)</td><td class="xxxx-borders">211 (49.9)</td><td class="xxxr-borders">211 (49.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">PASI score<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">9.8±10.0</td><td class="xxxx-borders shading">9.5±8.8</td><td class="xxxx-borders shading">11.2±11.4</td><td class="xxxr-borders shading">9.4±8.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on the sIGA of Psoriasis — no. (%)<a href="#t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">34 (7.9)</td><td class="xxxx-borders shading">21 (5.0)</td><td class="xxxx-borders shading">24 (5.7)</td><td class="xxxr-borders shading">34 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">73 (17.0)</td><td class="xxxx-borders">78 (18.4)</td><td class="xxxx-borders">86 (20.3)</td><td class="xxxr-borders">65 (15.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2</td><td class="xxxx-borders shading">170 (39.6)</td><td class="xxxx-borders shading">173 (40.9)</td><td class="xxxx-borders shading">167 (39.5)</td><td class="xxxr-borders shading">181 (42.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3</td><td class="xxxx-borders">133 (31.0)</td><td class="xxxx-borders">128 (30.3)</td><td class="xxxx-borders">119 (28.1)</td><td class="xxxr-borders">132 (30.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4</td><td class="xxxx-borders shading">19 (4.4)</td><td class="xxxx-borders shading">23 (5.4)</td><td class="xxxx-borders shading">27 (6.4)</td><td class="xxxr-borders shading">17 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Presence of enthesitis — no. (%)<a href="#t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">270 (62.9)</td><td class="xxxx-borders">267 (63.1)</td><td class="xxxx-borders">241 (57.0)</td><td class="xxxr-borders">265 (61.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Presence of dactylitis — no. (%)<a href="#t1fn11" role="doc-noteref">¶¶</a></td><td class="xbxx-borders shading">136 (31.7)</td><td class="xbxx-borders shading">127 (30.0)</td><td class="xbxx-borders shading">126 (29.8)</td><td class="xbxr-borders shading">127 (29.6)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Upadacitinib at either dose was administered orally once daily, and adalimumab was administered subcutaneously at a dose of 40 mg every other week. DMARD denotes disease-modifying antirheumatic drug.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Permitted concomitant nonbiologic DMARDs included methotrexate, sulfasalazine, leflunomide, apremilast, hydroxychloroquine, bucillamine, and iguratimod.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">The upper limit of the normal range (ULN) for C-reactive protein is 2.87 mg per liter.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Scores on the Health Assessment Questionnaire–Disability Index (HAQ-DI) range from 0 to 3, with higher scores indicating worse disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Scores for the patient’s assessment of pain were on a numerical rating scale from 0 to 10, with higher scores indicating greater severity of pain.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">Shown is the score on the Psoriasis Area and Severity Index (PASI; range, 0 to 72, with higher scores indicating greater severity of psoriasis) among patients with an affected body-surface area of at least 3%.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t1fn9" role="paragraph">Scores on the Static Investigator Global Assessment (sIGA) of Psoriasis range from 0 to 4, with higher scores indicating more severe skin involvement.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t1fn10" role="paragraph">The presence of enthesitis was defined by a score greater than 0 on the Leeds Enthesitis Index (range, 0 to 6, with higher scores indicating more affected sites).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="t1fn11" role="paragraph">The presence of dactylitis was defined by a score greater than 0 on the Leeds Dactylitis Index (higher scores indicate more affected sites).</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">At week 12, an ACR20 response (primary end point) occurred in 303 patients (70.6%) receiving the 15-mg dose of upadacitinib, in 332 (78.5%) receiving the 30-mg dose of upadacitinib, in 153 (36.2%) receiving placebo, and in 279 (65.0%) receiving adalimumab (<a href="#f1">Figure 1A</a> and <a href="#t2">Table 2</a>). The between-group differences were as follows: 15-mg dose of upadacitinib as compared with placebo, 34.5 percentage points (95% confidence interval [CI], 28.2 to 40.7; P&lt;0.001); 30-mg dose of upadacitinib as compared with placebo, 42.3 percentage points (95% CI, 36.3 to 48.3; P&lt;0.001); 15-mg dose of upadacitinib as compared with adalimumab, 5.6 percentage points (95% CI, −0.6 to 11.8; the hierarchical analysis failed at this point, so no P value is given); and 30-mg dose of upadacitinib as compared with adalimumab, 13.5 percentage points (95% CI, 7.5 to 19.4; P&lt;0.001).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2022516_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2022516_f1.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/478506ca-9706-427f-9dc8-3e91b611d73c/assets/images/large/nejmoa2022516_f1.jpg" height="3438" width="1644" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">ACR20, ACR50, and ACR70 Responses over a Period of 24 Weeks.</div><div class="notes"><div role="doc-footnote">Patients were randomly assigned to receive oral upadacitinib at a dose of 15 mg or 30 mg once daily, placebo, or subcutaneous adalimumab at a dose of 40 mg every other week. Panel A shows the percentage of patients with at least 20% improvement in the American College of Rheumatology (ACR) response criteria (ACR20 response). P&lt;0.001 for the comparisons of the two upadacitinib doses with placebo with respect to the ACR20 response at 12 weeks (primary end point) and for the comparison of the 30-mg dose of upadacitinib with adalimumab. The noninferiority criterion was met for both upadacitinib doses as compared with adalimumab. Panel B shows the percentage of patients with at least 50% improvement in ACR response criteria (ACR50 response), and Panel C shows the percentage of patients with at least 70% improvement (ACR70 response). Missing data were imputed as nonresponse. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t2.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/6aab9260-e4da-478d-a5d0-f0dac55f54ae/assets/images/large/nejmoa2022516_t2.jpg" height="3339" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Primary</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ACR20 response at wk 12 — no. (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">303 (70.6)</td><td class="xxxx-borders">332 (78.5)</td><td class="xxxx-borders">153 (36.2)</td><td class="xxxr-borders">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">34.5 (28.2 to 40.7); P&lt;0.001</td><td class="xxxx-borders">42.3 (36.3 to 48.3); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Secondary</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Least-squares mean change in HAQ-DI score at wk 12 (95% CI)</td><td class="xxxx-borders">−0.42 (−0.47 to −0.37) [404]</td><td class="xxxx-borders">−0.47 (−0.52 to −0.42) [398]</td><td class="xxxx-borders">−0.14 (−0.18 to −0.09) [392]</td><td class="xxxr-borders">−0.34 (−0.38 to −0.29) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders">−0.28 (−0.35 to −0.22); P&lt;0.001</td><td class="xxxx-borders">−0.34 (−0.40 to −0.27); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score on the sIGA of Psoriasis of 0 or 1 and a decrease of ≥2 points from baseline at wk 16 — no./total no. (%) <a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">135/322 (41.9)</td><td class="xxxx-borders shading">175/324 (54.0)</td><td class="xxxx-borders shading">34/313 (10.9)</td><td class="xxxr-borders shading">127/330 (38.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders shading">31.1 (24.7 to 37.5); P&lt;0.001</td><td class="xxxx-borders shading">43.1 (36.7 to 49.6); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">PASI75 response at wk 16 — no./total no. (%) <a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">134/214 (62.6)</td><td class="xxxx-borders">131/210 (62.4)</td><td class="xxxx-borders">45/211 (21.3)</td><td class="xxxr-borders">112/211 (53.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">41.3 (32.8 to 49.8); P&lt;0.001</td><td class="xxxx-borders">41.1 (32.5 to 49.6); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in mTSS at wk 24 (95% CI)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">−0.04 (−0.16 to 0.07) [391]</td><td class="xxxx-borders shading">0.03 (−0.08 to 0.15) [383]</td><td class="xxxx-borders shading">0.25 (0.13 to 0.36) [372]</td><td class="xxxr-borders shading">0.01 (−0.11 to 0.13) [384]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">−0.29 (−0.44 to −0.14); P&lt;0.001</td><td class="xxxx-borders shading">−0.21 (−0.36 to −0.06); P=0.007</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Minimal disease activity at wk 24 — no. (%)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">157 (36.6)</td><td class="xxxx-borders">192 (45.4)</td><td class="xxxx-borders">52 (12.3)</td><td class="xxxr-borders">143 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">24.3 (18.8 to 29.8); P&lt;0.001</td><td class="xxxx-borders">33.1 (27.4 to 38.8); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Resolution of enthesitis at wk 24 — no./total no. (%)<a href="#t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">145/270 (53.7)</td><td class="xxxx-borders shading">154/267 (57.7)</td><td class="xxxx-borders shading">78/241 (32.4)</td><td class="xxxr-borders shading">125/265 (47.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders shading">21.3 (13.0 to 29.7); P&lt;0.001</td><td class="xxxx-borders shading">25.3 (16.9 to 33.7); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ACR20 response at wk 12: noninferiority of upadacitinib to adalimumab — no. (%)</td><td class="xxxx-borders">303 (70.6)</td><td class="xxxx-borders">332 (78.5)</td><td class="xxxx-borders">153 (36.2)</td><td class="xxxr-borders">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percentage of adalimumab effect preserved (95% CI)<a href="#t2fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">119.4 (98.0 to 147.9); P&lt;0.001</td><td class="xxxx-borders">146.6 (122.8 to 180.4); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in SF-36 PCS score at wk 12 (95% CI)<a href="#t2fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">7.9 (7.1 to 8.6) [405]</td><td class="xxxx-borders shading">8.9 (8.1 to 9.7) [398]</td><td class="xxxx-borders shading">3.2 (2.4 to 4.0) [394]</td><td class="xxxr-borders shading">6.8 (6.1 to 7.6) [410]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">4.7 (3.7 to 5.7); P&lt;0.001</td><td class="xxxx-borders shading">5.7 (4.7 to 6.7); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Least-squares mean change in FACIT-Fatigue score (95% CI)<a href="#t2fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">6.3 (5.4 to 7.2) [404]</td><td class="xxxx-borders">7.1 (6.2 to 8.0) [398]</td><td class="xxxx-borders">2.8 (1.9 to 3.7) [394]</td><td class="xxxr-borders">5.7 (4.8 to 6.6) [410]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders">3.5 (2.4 to 4.7); P&lt;0.001</td><td class="xxxx-borders">4.3 (3.1 to 5.5); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">ACR20 response at wk 12: superiority of upadacitinib to adalimumab — no. (%)</td><td class="xxxx-borders shading">303 (70.6)</td><td class="xxxx-borders shading">332 (78.5)</td><td class="xxxx-borders shading">153 (36.2)</td><td class="xxxr-borders shading">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. adalimumab — percentage points (95% CI)</td><td class="xxxx-borders shading">5.6 (−0.6 to 11.8)<a href="#t2fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders shading">13.5 (7.5 to 19.4); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Resolution of dactylitis at wk 24 — no./total no. (%)<a href="#t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders">104/136 (76.5)</td><td class="xxxx-borders">101/127 (79.5)</td><td class="xxxx-borders">50/126 (39.7)</td><td class="xxxr-borders">94/127 (74.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">36.8 (25.7 to 47.9)</td><td class="xxxx-borders">39.8 (28.8 to 50.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in patient’s assessment of pain at wk 12: superiority of upadacitinib to adalimumab (95% CI)<a href="#t2fn13" role="doc-noteref">***</a></td><td class="xxxx-borders shading">−2.3 (−2.5 to −2.0) [404]</td><td class="xxxx-borders shading">−2.7 (−2.9 to −2.5) [398]</td><td class="xxxx-borders shading">−0.9 (−1.2 to −0.7) [392]</td><td class="xxxr-borders shading">−2.3 (−2.5 to −2.1) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. adalimumab (95% CI)</td><td class="xxxx-borders shading">0.0 (−0.3 to 0.3)</td><td class="xxxx-borders shading">−0.5 (−0.7 to −0.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change in HAQ-DI score at wk 12: superiority of upadacitinib to adalimumab</td><td class="xxxx-borders">−0.42 (−0.47 to −0.37) [404]</td><td class="xxxx-borders">−0.47 (−0.52 to −0.42) [398]</td><td class="xxxx-borders">−0.14 (−0.18 to −0.09) [392]</td><td class="xxxr-borders">−0.34 (−0.38 to −0.29) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. adalimumab (95% CI)</td><td class="xxxx-borders">−0.08 (−0.15 to −0.01)</td><td class="xxxx-borders">−0.14 (−0.20 to −0.07)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in Self-Assessment of Psoriasis Symptoms score at wk 16 — (95% CI)<a href="#t2fn14" role="doc-noteref">†††</a></td><td class="xxxx-borders shading">−25.3 (−27.3 to −23.4) [396]</td><td class="xxxx-borders shading">−28.1 (−30.0 to −26.1) [395]</td><td class="xxxx-borders shading">−8.2 (−10.2 to −6.3) [388]</td><td class="xxxr-borders shading">−22.7 (−24.7 to −20.8) [407]</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xbxx-borders shading">−17.1 (−19.6 to −14.6)</td><td class="xbxx-borders shading">−19.8 (−22.3 to −17.3)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The primary and secondary efficacy end points were subject to a graphical testing procedure to control for the global type I error. For continuous end points, the number of patients with available data is shown in brackets.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Patients with an American College of Rheumatology 20 (ACR20) response had a decrease from baseline of at least 20% in the number of tender and swollen joints and an improvement of at least 20% in at least three of five other domains.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Results were assessed in patients with baseline score of at least 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">A PASI75 response indicates a decrease of at least 75% from baseline in the PASI score. Results were assessed in patients with an affected body-surface area of at least 3% at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Values for the modified total Sharp–van der Heijde Score (mTSS) range from 0 to 528, with higher scores indicating greater damage.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Minimal disease activity was determined by fulfilling five of seven criteria: a tender-joint count of 0 or 1; a swollen-joint count of 0 or 1; a PASI score of 0 or 1 or an affected body-surface area of 3% or less; a score on the patient assessment of pain of 1.5 or less (range, 0 to 10, with higher scores indicating more pain); a score on the patient’s global assessment of disease activity of 2 or less (range, 0 to 10, with higher scores indicating more disease activity); a HAQ-DI score of 0.5 or less; and a score on the Leeds Enthesitis Index of 0 or 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">Resolution of enthesitis was defined by a score of 0 on the Leeds Enthesitis Index. Results were assessed in patients with a baseline score greater than 0.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t2fn8" role="paragraph">The percentage of adalimumab effect preserved was based on Koch’s three-group noninferiority approach and calculated as [(upadacitinib−placebo) ÷ (adalimumab−placebo)×100%].</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t2fn9" role="paragraph">Norm-based scores were used for the score on the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS), with higher scores indicating better health-related quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t2fn10" role="paragraph">Scores on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) range from 0 to 52, with higher scores indicating less fatigue.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="t2fn11" role="paragraph">For the secondary end points, hierarchical testing failed at the end point of “ACR20 response at week 12: superiority of upadacitinib to adalimumab” in the comparison of the 15-mg dose of upadacitinib with adalimumab.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="t2fn12" role="paragraph">Resolution of dactylitis was defined by a score of 0 on the Leeds Dactylitis Index. Results were assessed in patients with a baseline score greater than 0.</div></div><div role="doc-footnote" data-has="label"><div class="label">***</div><div id="t2fn13" role="paragraph">The patient’s assessment of pain was determined on the same scale as in the criterion for minimal disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">†††</div><div id="t2fn14" role="paragraph">Scores on the Self-Assessment of Psoriasis Symptoms range from 0 to 110, with higher scores indicating greater severity of symptoms.</div></div></div></figcaption></figure></div><div role="paragraph">On the basis of Koch’s three-group noninferiority method, the adalimumab effect preservation was 119.4% (95% CI, 98.0 to 147.9) with the 15-mg dose of upadacitinib and 146.6% (95% CI, 122.8 to 180.4) with the 30-mg dose of upadacitinib, findings that showed noninferiority of both doses to adalimumab, because the lower boundary of the 95% confidence interval was above the prespecified threshold of 50%. The originally prespecified analysis that used a noninferiority margin of 15 percentage points gave similar results to the Koch analysis (Fig. S4). The 30-mg dose of upadacitinib was superior to adalimumab in achieving an ACR20 response, but the 15-mg dose of upadacitinib was not superior to adalimumab, which prevented the testing of significance for secondary end points lower in the end-point hierarchy.</div><div role="paragraph">Additional end points of clinical importance in psoriatic arthritis that were analyzed in the statistical hierarchy and for which results were significantly better with both doses of upadacitinib than with placebo were the change from baseline in the HAQ-DI score, the percentage of patients with a score on the sIGA of Psoriasis of 0 or 1 and at least a 2-point decrease from baseline, the percentage of patients with a PASI75 response, the change from baseline in the modified total Sharp–van der Heijde Score, the percentage of patients in whom minimal disease activity was achieved and resolution of enthesitis occurred, and the change from baseline in the SF-36 PCS and FACIT-Fatigue scores (<a href="#t2">Table 2</a> and Figs. S5 through S10, S12, and S13). Sensitivity analyses for the change from baseline in the HAQ-DI, SF-36 PCS, and FACIT-Fatigue scores yielded similar results (Table S3).</div><div role="paragraph">End points that could not be analyzed owing to failure of the hierarchy at the point of ACR20 response with upadacitinib at a dose of 15 mg as compared with adalimumab include resolution of dactylitis comparing upadacitinib with placebo and the change from baseline in the patient’s assessment of pain with upadacitinib as compared with adalimumab, the change from baseline in the HAQ-DI score as compared with adalimumab, and the change from baseline in the Self-Assessment of Psoriasis Symptoms as compared with placebo. Responses to adalimumab as compared with upadacitinib are shown in <a href="#t2">Table 2</a> and Figures S5 through S10, S12, and S13.</div><div role="paragraph">ACR50 and ACR70 responses are of special interest to the field of rheumatology, and comparisons of the 15-mg and 30-mg doses of upadacitinib with placebo and with adalimumab for these end points were prespecified; however, confidence intervals were not adjusted for multiple comparisons, and no conclusions can be drawn from the results. The results of the comparisons of the two doses of upadacitinib with placebo with respect to ACR50 and ACR70 responses were generally in the same direction as those for the primary end point and for the comparison of the 30-mg dose of upadacitinib with adalimumab. No significant differences were noted in the comparison of the 15-mg dose of upadacitinib with adalimumab for the ACR50 or ACR70 response at 12 weeks; confidence intervals at 12 and 24 weeks are shown in Table S4. Results for additional end points, including different time points for the primary and secondary end points, are shown in <a href="#f1">Figure 1</a> and Figures S5 through S14.</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph"><a id="exam-tint-three-c"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-c">Through week 24, the incidences of adverse events and serious adverse events, including serious infections, were similar with the 15-mg dose of upadacitinib and adalimumab but were more frequent with the 30-mg dose of upadacitinib (<a href="#t3">Table 3</a>). The most common adverse event was upper respiratory tract infection (Table S5). The incidence of serious infections was 1.2% with the 15-mg dose of upadacitinib, 2.6% with the 30-mg dose of upadacitinib, 0.9% with placebo, and 0.7% with adalimumab.</span> Up to week 24, opportunistic infections included one case of candida urethritis with the 15-mg dose of upadacitinib and one case each of <i>Pneumocystis jirovecii</i> pneumonia and cytomegalovirus with the 30-mg dose of upadacitinib. Herpes zoster was diagnosed in four patients receiving the 15-mg dose of upadacitinib, in five receiving the 30-mg dose of upadacitinib, in three receiving placebo, and in none receiving adalimumab. Cancer occurred in one patient each in the 15-mg upadacitinib and placebo groups and in three patients each in the 30-mg upadacitinib and adalimumab groups; the types of cancer are shown in <a href="#t3">Table 3</a>. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-d">No major adverse cardiovascular events were reported with upadacitinib. One pulmonary embolism was reported with the 30-mg dose of upadacitinib; one case of deep-vein thrombosis was reported with placebo and two cases with adalimumab. One death, adjudicated to be of unknown cause, was reported with placebo.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t3.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/a44e22a3-e9fe-475e-a7f2-d71d12587e19/assets/images/large/nejmoa2022516_t3.jpg" height="2871" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event or Variable</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patients with adverse events — no. (%)</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">287 (66.9)</td><td class="xxxx-borders">306 (72.3)</td><td class="xxxx-borders">252 (59.6)</td><td class="xxxr-borders">278 (64.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">14 (3.3)</td><td class="xxxx-borders shading">26 (6.1)</td><td class="xxxx-borders shading">13 (3.1)</td><td class="xxxr-borders shading">16 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of placebo, upadacitinib, or adalimumab</td><td class="xxxx-borders">13 (3.0)</td><td class="xxxx-borders">21 (5.0)</td><td class="xxxx-borders">13 (3.1)</td><td class="xxxr-borders">22 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Infection</td><td class="xxxx-borders">169 (39.4)</td><td class="xxxx-borders">183 (43.3)</td><td class="xxxx-borders">140 (33.1)</td><td class="xxxr-borders">146 (34.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">11 (2.6)</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxr-borders shading">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Opportunistic</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">2 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Herpes zoster<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">3 (0.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Active tuberculosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hepatic disorder</td><td class="xxxx-borders shading">39 (9.1)</td><td class="xxxx-borders shading">52 (12.3)</td><td class="xxxx-borders shading">16 (3.8)</td><td class="xxxr-borders shading">67 (15.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cancer<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonmelanoma skin cancer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.5)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cancer other than nonmelanoma skin cancer</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymphoma</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Anemia</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxx-borders">20 (4.7)</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neutropenia</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">21 (5.0)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">10 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">6 (1.4)</td><td class="xxxx-borders">15 (3.5)</td><td class="xxxx-borders">5 (1.2)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Elevated creatine kinase level</td><td class="xxxx-borders shading">38 (8.9)</td><td class="xxxx-borders shading">41 (9.7)</td><td class="xxxx-borders shading">6 (1.4)</td><td class="xxxr-borders shading">24 (5.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Renal dysfunction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major adverse cardiovascular event<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">2 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Venous thromboembolism<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">2 (0.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Least-squares mean change in laboratory measures from baseline to wk 24</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders">−0.7±9.8</td><td class="xxxx-borders">−2.7±9.6</td><td class="xxxx-borders">0.0±7.7</td><td class="xxxr-borders">2.7±9.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neutrophils — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders shading">−0.515±1.939</td><td class="xxxx-borders shading">−0.834±1.856</td><td class="xxxx-borders shading">0.052±1.659</td><td class="xxxr-borders shading">−1.015±1.695</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Lymphocytes — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders">0.064±0.527</td><td class="xxxx-borders">0.143±0.604</td><td class="xxxx-borders">0.095±0.419</td><td class="xxxr-borders">0.443±0.575</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Platelets — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders shading">−2.1±57.7</td><td class="xxxx-borders shading">6.7±58.7</td><td class="xxxx-borders shading">−4.7±55.4</td><td class="xxxr-borders shading">−20.3±50.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">LDL cholesterol — mmol/liter</td><td class="xxxx-borders">0.408±0.790</td><td class="xxxx-borders">0.447±0.809</td><td class="xxxx-borders">0.025±0.619</td><td class="xxxr-borders">0.034±0.634</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">HDL cholesterol — mmol/liter</td><td class="xxxx-borders shading">0.223±0.270</td><td class="xxxx-borders shading">0.249±0.294</td><td class="xxxx-borders shading">0.003±0.230</td><td class="xxxr-borders shading">0.080±0.270</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ALT — U/liter</td><td class="xxxx-borders">6.1±20.7</td><td class="xxxx-borders">7.9±23.4</td><td class="xxxx-borders">−1.0±16.9</td><td class="xxxr-borders">5.0±19.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">AST — U/liter</td><td class="xxxx-borders shading">5.7±13.8</td><td class="xxxx-borders shading">7.1±12.5</td><td class="xxxx-borders shading">−1.1±15.3</td><td class="xxxr-borders shading">2.9±13.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Creatinine — μmol/liter</td><td class="xxxx-borders">4.7±10.1</td><td class="xxxx-borders">6.3±8.8</td><td class="xxxx-borders">1.6±8.8</td><td class="xxxr-borders">4.1±39.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Creatine kinase — U/liter</td><td class="xbxx-borders shading">85.2±110.8</td><td class="xbxx-borders shading">140.0±342.8</td><td class="xbxx-borders shading">20.0±331.3</td><td class="xbxr-borders shading">25.8±105.3</td></tr></tbody></table></div><figcaption><div class="caption">Safety Summary through Week 24.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Plus–values are means ±SD. Adverse events were coded according to the <i>Medical Dictionary for Regulatory Activities</i>. Laboratory data were graded with the use of the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.03. Changes in laboratory variables are reported on the basis of single measurements. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for creatinine to milligrams per deciliter, divide by 88.4. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, HDL high-density lipoprotein, and LDL low-density lipoprotein.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">All cases of herpes zoster were nonserious and mild or moderate in severity, without ophthalmic, central nervous system, or other internal organ involvement.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">In the placebo group, one patient had basal-cell carcinoma. In the 15-mg upadacitinib group, one patient had neuroendocrine carcinoma. In the 30-mg upadacitinib group, two patients had basal-cell carcinoma and one had a malignant lung neoplasm. In the adalimumab group, one patient each had colon cancer, ovarian cancer, and uterine cancer.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Major adverse cardiovascular events were defined as nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes and were adjudicated by an independent committee whose members were unaware of the trial group assignments.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">Venous thromboembolism was defined as deep-vein thrombosis or pulmonary embolism. Cases were adjudicated by an independent committee whose members were unaware of the trial group assignments.</div></div></div></figcaption></figure></div><div role="paragraph">Mean hemoglobin, neutrophil, lymphocyte, and platelet levels remained within normal limits from baseline through week 24 in all trial groups (Table S6 and Fig. S17). Anemia and lymphopenia adverse events were reported at similar incidences with the 15-mg dose of upadacitinib and placebo but were more frequent with the 30-mg dose of upadacitinib (<a href="#t3">Table 3</a>). Neutropenia adverse events were more common with upadacitinib than with placebo. Overall, the frequency of laboratory abnormalities of grade 3 or higher was no more than 2.1% (Table S7). One patient each had a grade 3 decrease in hemoglobin level or platelet count after discontinuation of the 30-mg dose of upadacitinib. The frequency of grade 3 decreases in neutrophil and lymphocyte levels was higher in the 30-mg upadacitinib group than in the other groups.</div><div role="paragraph">The incidence of adverse events involving hepatic disorders was 9.1% in the 15-mg upadacitinib group, 12.3% in the 30-mg upadacitinib group, 3.8% in the placebo group, and 15.6% in the adalimumab group. Most increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels were of grade 2 or less. Grade 3 elevations in ALT levels occurred in 0.9% with the 15-mg dose of upadacitinib, 1.2% with the 30-mg dose of upadacitinib, 1.7% with placebo, and 0.9% with adalimumab. Grade 3 elevations in AST levels occurred in 0%, 0.7%, 0.5%, and 0.2% with the 15-mg dose of upadacitinib, the 30-mg dose of upadacitinib, placebo, and adalimumab, respectively. One patient in the 30-mg upadacitinib group had a grade 4 increase in the AST level at a single time point. No patients met Hy’s law criteria suggestive of drug-induced liver injury. Grade 3 or 4 increases in creatine kinase levels were more common with upadacitinib than with adalimumab and placebo; no patients had rhabdomyolysis. Increases in levels of low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were observed more often with upadacitinib than with placebo (Fig. S18). The ratio of LDL cholesterol to HDL cholesterol and the ratio of total cholesterol to HDL cholesterol did not change substantially through week 24.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This trial compared upadacitinib at a dose of 15 mg or 30 mg once daily with placebo and used adalimumab as an active comparator over a period of 24 weeks in patients with psoriatic arthritis who had an inadequate response to nonbiologic DMARDs. The results for most musculoskeletal end points were significantly better with upadacitinib than placebo. <span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The 15-mg and 30-mg doses of upadacitinib were noninferior to adalimumab with respect to the ACR20 response at week 12; the 30-mg dose, but not the 15-mg dose, was superior to adalimumab with respect to the ACR20 response.</span> Results were better with both upadacitinib doses than with placebo in other aspects of psoriatic arthritis, including objective measures of psoriasis activity, achievement of minimal disease activity and resolution of enthesitis, physical function, fatigue, quality of life, and inhibition of radiographic progression. Additional outcomes, including resolution of dactylitis, patient-reported improvement in psoriasis symptoms, and additional comparisons with adalimumab, could not be analyzed owing to failure of the hierarchical analysis.</div><div role="paragraph">There are limited data on which to base assumptions for comparisons of upadacitinib with adalimumab. This resulted in challenges in selecting end points comparing upadacitinib with adalimumab, in powering comparisons between upadacitinib doses and with adalimumab, and in selecting a noninferiority margin. Because the sample size was similar to the collective sample sizes of the adalimumab and placebo groups in previous trials, the inclusion of placebo, adalimumab, and upadacitinib groups allowed estimation of the adalimumab treatment effect as compared with placebo to establish noninferiority. At the time of trial design, the appropriate end point for comparison with an active comparator was undefined and ACR20 response was the generally accepted primary end point for studies involving patients with psoriatic arthritis.</div><div role="paragraph">The safety profile of upadacitinib was generally similar to that reported previously in trials involving patients with rheumatoid arthritis, but direct comparisons of adverse events between trials for these two diseases cannot be made.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5" id="body-ref-r5-2" href-manipulated="true">1-5</a></sup> Serious infections were more frequent with the 30-mg dose of upadacitinib than with placebo or adalimumab. The incidences of herpes zoster were similar and were approximately 1% for both doses of upadacitinib and placebo. Dose-dependent elevations in creatine kinase levels were reported with upadacitinib. Adverse events involving hepatic disorders were observed with upadacitinib, and grade 3 increases in ALT or AST levels were reported in 2% or less of patients across all groups. Dose-dependent increases in LDL and HDL cholesterol levels were observed with upadacitinib without changes in serum lipid ratios. No major adverse cardiovascular events were reported with upadacitinib. One pulmonary embolism occurred with the 30-mg dose of upadacitinib. Owing to the 24-week duration of the placebo-controlled portion of this trial, limited safety conclusions can be made for events that could emerge with longer use of upadacitinib or adalimumab.</div><div role="paragraph">In this trial, upadacitinib at a dose of 15 mg or 30 mg once daily was more effective than placebo in most measures of psoriatic arthritis activity and inhibited radiographic progression of disease. Both upadacitinib doses were noninferior to adalimumab; the 30-mg dose but not the 15-mg dose of upadacitinib was superior to adalimumab with respect to the ACR20 response at week 12. There were more adverse events with either dose of upadacitinib than with placebo and more serious adverse events with the 30-mg dose of upadacitinib. Longer and larger trials are required to determine the effect and risks of upadacitinib and its effects as compared with other drugs used to treat psoriatic arthritis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">AbbVie</span>.</div><div role="paragraph">Dr. McInnes reports receiving consulting fees from AbbVie, Crescendo, Gilead Sciences, Janssen Biotech, Novartis, Pfizer, and Sanofi Pasteur, receiving grant support, paid to the University of Glasgow, and consulting fees from Amgen, receiving grant support, paid to his institution, and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and UCB, owning stock options in Cabaletta Bio, and receiving grant support, paid to his institution, and consulting fees from and owning stock options in Compugen; Dr. Anderson, being employed by and owning stock in AbbVie; Dr. Magrey, receiving grant support, paid to MetroHealth, and meal reimbursement from AbbVie and Amgen, grant support, paid to MetroHealth, from Celgene, UCB (Germany), and UCB (Belgium), advisory board fees and travel support from Eli Lilly, advisory board fees from Janssen Biotech and Pfizer, grant support, advisory board fees, and travel support from Novartis, consulting fees from Rockpointe, and grant support, paid to MetroHealth, advisory board fees, and travel support from UCB BioSciences; Dr. Merola, receiving consulting fees from AbbVie, Dermavant Sciences, Eli Lilly, Janssen Biotech, Novartis, and UCB; Dr. Kishimoto, receiving advisory board fees and lecture fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Novartis Pharma, Ono, Pfizer, and UCB and lecture fees from Asahi Kasei Medical, Astellas Pharma, Ayumi Pharma, Boehringer Ingelheim, Celltrion Healthcare, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, and Teijin Pharma; Dr. Pacheco-Tena, receiving grant support from AbbVie, AstraZeneca, Eli Lilly, Janssen Biotech, Pfizer, and R-Pharm US; Dr. Wang, Ms. Chen, and Drs. Zueger, J. Liu, and Pangan, being employed by and owning stock in AbbVie; and Dr. Behrens, receiving advisory board fees, lecture fees, and consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Genzyme, Merck Sharp &amp; Dohme, Novartis, and Sanofi, grant support, paid to Fraunhofer Institute of Molecular Biology and Applied Ecology–Project Group Translational Medicine and Pharmacology, consulting fees, advisory board fees, and lecture fees from Celgene, F. Hoffmann–La Roche, Janssen Pharmaceuticals, and Pfizer, grant support, paid to Rheumazentrum, advisory board fees, lecture fees, and consulting fees from Chugai Pharmaceutical, and advisory board fees and lecture fees from UCB. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients, staff of the trial sites, and investigators who participated in this clinical trial, and Ramona Vladea of AbbVie for medical writing support.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2022516_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2022516/suppl_file/nejmoa2022516_protocol.pdf" download="nejmoa2022516_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2022516_protocol.pdf" data-doi="10.1056/NEJMoa2022516">Download</a></li><li>4.01 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2022516_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2022516/suppl_file/nejmoa2022516_appendix.pdf" download="nejmoa2022516_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2022516_appendix.pdf" data-doi="10.1056/NEJMoa2022516">Download</a></li><li>970.72 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2022516_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2022516/suppl_file/nejmoa2022516_disclosures.pdf" download="nejmoa2022516_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2022516_disclosures.pdf" data-doi="10.1056/NEJMoa2022516">Download</a></li><li>715.07 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2022516_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2022516/suppl_file/nejmoa2022516_data-sharing.pdf" download="nejmoa2022516_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2022516_data-sharing.pdf" data-doi="10.1056/NEJMoa2022516">Download</a></li><li>69.68 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. <em>Lancet</em> 2018;391:2503-2512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31115-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29908669/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436403700024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+upadacitinib+in+patients+with+rheumatoid+arthritis+and+inadequate+response+to+conventional+synthetic+disease-modifying+anti-rheumatic+drugs+%28SELECT-NEXT%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2503-2512&amp;doi=10.1016%2FS0140-6736%2818%2931115-2&amp;pmid=29908669" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. <em>Arthritis Rheumatol</em> 2019;71:1788-1800.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31287230/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Upadacitinib+versus+placebo+or+adalimumab+in+patients+with+rheumatoid+arthritis+and+an+inadequate+response+to+methotrexate%3A+results+of+a+phase+III%2C+double-blind%2C+randomized+controlled+trial.&amp;publication_year=2019&amp;journal=Arthritis+Rheumatol&amp;pages=1788-1800&amp;doi=10.1002%2Fart.41032&amp;pmid=31287230" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <em>Lancet</em> 2018;391:2513-2524.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31116-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29908670/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436403700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+upadacitinib+in+patients+with+active+rheumatoid+arthritis+refractory+to+biologic+disease-modifying+anti-rheumatic+drugs+%28SELECT-BEYOND%29%3A+a+double-blind%2C+randomised+controlled+phase+3+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2513-2524&amp;doi=10.1016%2FS0140-6736%2818%2931116-4&amp;pmid=29908670" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <em>Lancet</em> 2019;393:2303-2311.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)30419-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31130260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000470263400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Upadacitinib+as+monotherapy+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+%28SELECT-MONOTHERAPY%29%3A+a+randomised%2C+placebo-controlled%2C+double-blind+phase+3+study.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2303-2311&amp;doi=10.1016%2FS0140-6736%2819%2930419-2&amp;pmid=31130260" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. <em>Arthritis Rheumatol</em> 2020 July 8 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41384" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32638504/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+upadacitinib+monotherapy+in+methotrexate-na%C3%AFve+patients+with+moderately+to+severely+active+rheumatoid+arthritis+%28SELECT-EARLY%29%3A+a+randomized%2C+double-blind%2C+active-comparator%2C+multi-center%2C+multi-country+trial.&amp;publication_year=2020&amp;journal=Arthritis+Rheumatol&amp;doi=10.1002%2Fart.41384&amp;pmid=32638504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <em>Arthritis Rheum</em> 2006;54:2665-2673.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.21972" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16871531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239641400037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Classification+criteria+for+psoriatic+arthritis%3A+development+of+new+criteria+from+a+large+international+study.&amp;publication_year=2006&amp;journal=Arthritis+Rheum&amp;pages=2665-2673&amp;doi=10.1002%2Fart.21972&amp;pmid=16871531" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. <em>J Rheumatol</em> 1982;9:789-793.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7175852/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PQ06200032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+dimensions+of+health+outcomes%3A+the+health+assessment+questionnaire%2C+disability+and+pain+scales.&amp;publication_year=1982&amp;journal=J+Rheumatol&amp;pages=789-793&amp;pmid=7175852" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. <em>J Dermatolog Treat</em> 2015;26:23-31.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/09546634.2013.865009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24354461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350751100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+5-point+Investigator%E2%80%99s+Global+Assessment+%28IGA%29+Scale%3A+a+modified+tool+for+evaluating+plaque+psoriasis+severity+in+clinical+trials.&amp;publication_year=2015&amp;journal=J+Dermatolog+Treat&amp;pages=23-31&amp;doi=10.3109%2F09546634.2013.865009&amp;pmid=24354461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. <em>Dermatologica</em> 1978;157:238-244.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000250839" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/357213/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1978FJ96400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+psoriasis+%E2%80%94+oral+therapy+with+a+new+retinoid.&amp;publication_year=1978&amp;journal=Dermatologica&amp;pages=238-244&amp;doi=10.1159%2F000250839&amp;pmid=357213" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. <em>Ann Rheum Dis</em> 2010;69:48-53.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/ard.2008.102053" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19147615/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272594100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+minimal+disease+activity+in+psoriatic+arthritis%3A+a+proposed+objective+target+for+treatment.&amp;publication_year=2010&amp;journal=Ann+Rheum+Dis&amp;pages=48-53&amp;doi=10.1136%2Fard.2008.102053&amp;pmid=19147615" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. <em>Arthritis Rheum</em> 2008;59:686-691.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.23568" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18438903/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255848000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measuring+clinical+enthesitis+in+psoriatic+arthritis%3A+assessment+of+existing+measures+and+development+of+an+instrument+specific+to+psoriatic+arthritis.&amp;publication_year=2008&amp;journal=Arthritis+Rheum&amp;pages=686-691&amp;doi=10.1002%2Fart.23568&amp;pmid=18438903" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: Quality Metric, 2000.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Ware+JE%2C+Kosinski+M%2C+Dewey+JE.+How+to+score+version+two+of+the+SF-36+health+survey.+Lincoln%2C+RI%3A+Quality+Metric%2C+2000." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Cella D, Lai J-S, Chang C-H, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. <em>Cancer</em> 2002;94:528-538.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.10245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11900238/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000173303800031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fatigue+in+cancer+patients+compared+with+fatigue+in+the+general+United+States+population.&amp;publication_year=2002&amp;journal=Cancer&amp;pages=528-538&amp;doi=10.1002%2Fcncr.10245&amp;pmid=11900238" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. <em>J Rheumatol</em> 2005;32:1745-1750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16142872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000231921300021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+an+assessment+tool+for+dactylitis+in+patients+with+psoriatic+arthritis.&amp;publication_year=2005&amp;journal=J+Rheumatol&amp;pages=1745-1750&amp;pmid=16142872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Armstrong AW, Banderas B, Foley C, Stokes J, Sundaram M, Shields AL. Development and psychometric evaluation of the Self-Assessment of Psoriasis Symptoms (SAPS)–Clinical Trial and the SAPS–Real World patient-reported outcomes. <em>J Dermatolog Treat</em> 2017;28:505-514.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09546634.2017.1290206" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28147886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412796100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+and+psychometric+evaluation+of+the+Self-Assessment+of+Psoriasis+Symptoms+%28SAPS%29%E2%80%93Clinical+Trial+and+the+SAPS%E2%80%93Real+World+patient-reported+outcomes.&amp;publication_year=2017&amp;journal=J+Dermatolog+Treat&amp;pages=505-514&amp;doi=10.1080%2F09546634.2017.1290206&amp;pmid=28147886" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/13"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">13</span></span> • <span property="datePublished">April 1, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1227</span>-<span property="pageEnd">1239</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 31, 2021</div><div><b class="core-label">Published in issue</b>: April 1, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/psoriasis" alt="View article keyword Psoriasis" data-interactiontype="article_recirculation_click">Psoriasis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/rheumatoid-arthritis" alt="View article keyword Rheumatoid Arthritis" data-interactiontype="article_recirculation_click">Rheumatoid Arthritis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Iain B.</span> <span property="familyName">McInnes</span>, <span property="honorificSuffix">F.R.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jaclyn K.</span> <span property="familyName">Anderson</span>, <span property="honorificSuffix">D.O.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marina</span> <span property="familyName">Magrey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joseph F.</span> <span property="familyName">Merola</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yi</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mitsumasa</span> <span property="familyName">Kishimoto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Slawomir</span> <span property="familyName">Jeka</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cesar</span> <span property="familyName">Pacheco-Tena</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xin</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Liang</span> <span property="familyName">Chen</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patrick</span> <span property="familyName">Zueger</span>, <span property="honorificSuffix">Pharm.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Aileen L.</span> <span property="familyName">Pangan</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Frank</span> <span property="familyName">Behrens</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (I.B.M.); AbbVie, North Chicago, IL (J.K.A., X.W., L.C., P.Z., J.L., A.L.P.); Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland (M.M.); Brigham and Women’s Hospital and Harvard Medical School, Boston (J.F.M.); the Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China (Y.L.); the Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo (M.K.); the Department of Rheumatology and Connective Tissue Diseases, Collegium Medicum Uniwersytet Mikołaja Kopernika, 2nd University Hospital, Bydgoszcz, Poland (S.J.); Facultad de Medicina, Universidad Autonoma de Chihuahua, Chihuahua, Mexico (C.P.-T.); and Goethe University and Fraunhofer Institute for Molecular Biology and Applied Ecology–Branch for Translational Medicine and Pharmacology and Cluster of Excellence for Immune-Mediated Diseases, Frankfurt, Germany (F.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. McInnes at the University of Glasgow, Glasgow Biomedical Research Centre, 120 University Pl., Glasgow G128QQ, United Kingdom, or at <a href="mailto:iain.mcinnes@glasgow.ac.uk">iain.mcinnes@glasgow.ac.uk</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">204</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2022516" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="ad63a1b0-3f95-d5da-caba-0020b6a47011"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235" style="display:inline-block;">
                <img alt="Article has an altmetric score of 477" src="https://badges.altmetric.com/?size=320&amp;score=477&amp;types=mmbcttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_ad63a1b0-3f95-d5da-caba-0020b6a47011" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=news">
          Picked up by <b>61</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=twitter">
          Posted by <b>57</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=103072235&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>196</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6763b1396f211-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2022516"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2022516%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="204" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zeyu Chen, </li><li class="list-inline-item cited-by__entry__author">Suyang Lin, </li><li class="list-inline-item cited-by__entry__author">Lian Cui, </li><li class="list-inline-item cited-by__entry__author">Qian Yu, </li><li class="list-inline-item cited-by__entry__author">Yuling Shi, </li></ul><span class="cited-by__entry__title">Targeted immunotherapy of psoriasis: focusing on Janus kinase/signal transducers and activators of transcription signaling pathway, </span><span class="cited-by__entry__series-title">Current Opinion in Immunology, </span><span class="cited-by__entry__volume"><strong>95</strong>, </span><span class="cited-by__entry__page-range">(102583), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.coi.2025.102583" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.coi.2025.102583</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.coi.2025.102583" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fadi Kharouf, </li><li class="list-inline-item cited-by__entry__author">Shangyi Gao, </li><li class="list-inline-item cited-by__entry__author">Daniel Pereira, </li><li class="list-inline-item cited-by__entry__author">Cheryl F Rosen, </li><li class="list-inline-item cited-by__entry__author">Richard J Cook, </li><li class="list-inline-item cited-by__entry__author">Vinod Chandran, </li><li class="list-inline-item cited-by__entry__author">Dafna D Gladman, </li></ul><span class="cited-by__entry__title">Tuft resorption in patients with psoriatic arthritis, </span><span class="cited-by__entry__series-title">Seminars in Arthritis and Rheumatism, </span><span class="cited-by__entry__volume"><strong>72</strong>, </span><span class="cited-by__entry__page-range">(152701), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semarthrit.2025.152701" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semarthrit.2025.152701</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semarthrit.2025.152701" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">M. O. Klymenko, </li><li class="list-inline-item cited-by__entry__author">O.M. Tarasenko, </li><li class="list-inline-item cited-by__entry__author">V.I. Zaborovsky, </li><li class="list-inline-item cited-by__entry__author">M.E. Guk, </li></ul><span class="cited-by__entry__title">NODULAR FORMS OF OSTEOARTHRITIS, </span><span class="cited-by__entry__series-title">Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(310-318), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.31718/2077-1096.25.2.310" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.31718/2077-1096.25.2.310</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.31718/2077-1096.25.2.310" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yiming Zhao, </li><li class="list-inline-item cited-by__entry__author">Qian Liu, </li><li class="list-inline-item cited-by__entry__author">Jinmin Zhao, </li><li class="list-inline-item cited-by__entry__author">Dezhi Song, </li></ul><span class="cited-by__entry__title">The roles of natural killer cells in bone and arthritic disease: a narrative review, </span><span class="cited-by__entry__series-title">Immunological Medicine, </span><span class="cited-by__entry__page-range">(1-14), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/25785826.2025.2506260" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/25785826.2025.2506260</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/25785826.2025.2506260" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Eva Galíndez-Agirregoikoa, </li><li class="list-inline-item cited-by__entry__author">Diana Prieto-Peña, </li><li class="list-inline-item cited-by__entry__author">Maria Luz García-Vivar, </li><li class="list-inline-item cited-by__entry__author">Joaquin Maria Belzunegui Otano, </li><li class="list-inline-item cited-by__entry__author">Beatriz Joven-Ibáñez, </li><li class="list-inline-item cited-by__entry__author">Cristina Vergara-Dangond, </li><li class="list-inline-item cited-by__entry__author">Marina Pavía-Pascual, </li><li class="list-inline-item cited-by__entry__author">Irati Urionaguena-Onaindia, </li><li class="list-inline-item cited-by__entry__author">Lucia Vega Alvarez, </li><li class="list-inline-item cited-by__entry__author">M. Ángeles Puche Larrubia, </li><li class="list-inline-item cited-by__entry__author">Consuelo Ramos Giráldez, </li><li class="list-inline-item cited-by__entry__author">Rosario Garcia-Vicuña, </li><li class="list-inline-item cited-by__entry__author">Vega Jovani, </li><li class="list-inline-item cited-by__entry__author">Angels Martínez-Ferrer, </li><li class="list-inline-item cited-by__entry__author">Mireia Moreno Martínez-Losa, </li><li class="list-inline-item cited-by__entry__author">Teresa González Hernández, </li><li class="list-inline-item cited-by__entry__author">Raquel Almodóvar González, </li><li class="list-inline-item cited-by__entry__author">Ana Urruticoechea-Arana, </li><li class="list-inline-item cited-by__entry__author">Cristina Macía-Villa, </li><li class="list-inline-item cited-by__entry__author">Inigo Gorostiza, </li><li class="list-inline-item cited-by__entry__author">Ricardo Blanco Alonso, </li></ul><span class="cited-by__entry__title">Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice, </span><span class="cited-by__entry__series-title">Sci, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(67), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/sci7020067" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/sci7020067</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/sci7020067" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Algün Polat Ekinci, </li><li class="list-inline-item cited-by__entry__author">Fatma Kübra Çiftçi, </li></ul><span class="cited-by__entry__title">Dermatological Indications: Psoriasis, </span><span class="cited-by__entry__series-title">Jak-Inhibitors in Dermatology, </span><span class="cited-by__entry__page-range">(93-102), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/978-3-031-84274-0_12" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-3-031-84274-0_12</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-3-031-84274-0_12" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Diego Dominguez, </li><li class="list-inline-item cited-by__entry__author">Sawyer Vaclaw, </li><li class="list-inline-item cited-by__entry__author">Cynthia McClard, </li><li class="list-inline-item cited-by__entry__author">Matlock A. Jeffries, </li><li class="list-inline-item cited-by__entry__author">Jila Noori, </li></ul><span class="cited-by__entry__title">Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis, </span><span class="cited-by__entry__series-title">Journal of Ophthalmic and Vision Research, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__page-range">(1-6), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.18502/jovr.v20.14952" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.18502/jovr.v20.14952</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.18502/jovr.v20.14952" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Scott A. Elman, </li><li class="list-inline-item cited-by__entry__author">Lourdes M. Perez-Chada, </li><li class="list-inline-item cited-by__entry__author">April Armstrong, </li><li class="list-inline-item cited-by__entry__author">Alice B. Gottlieb, </li><li class="list-inline-item cited-by__entry__author">Joseph F. Merola, </li></ul><span class="cited-by__entry__title">Psoriatic arthritis: A comprehensive review for the dermatologist–Part II: Screening and management, </span><span class="cited-by__entry__series-title">Journal of the American Academy of Dermatology, </span><span class="cited-by__entry__volume"><strong>92</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(985-998), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jaad.2024.03.059" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jaad.2024.03.059</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jaad.2024.03.059" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sotirios G. Tsiogkas, </li><li class="list-inline-item cited-by__entry__author">Arriana Gkouvi, </li><li class="list-inline-item cited-by__entry__author">Katerina Maria Kontouli, </li><li class="list-inline-item cited-by__entry__author">Theodora Simopoulou, </li><li class="list-inline-item cited-by__entry__author">Maria G. Grammatikopoulou, </li><li class="list-inline-item cited-by__entry__author">Dimitrios P. Bogdanos, </li></ul><span class="cited-by__entry__title">Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis, </span><span class="cited-by__entry__series-title">Autoimmunity Reviews, </span><span class="cited-by__entry__volume"><strong>24</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(103819), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.autrev.2025.103819" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.autrev.2025.103819</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.autrev.2025.103819" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Victoria Konzett, </li><li class="list-inline-item cited-by__entry__author">Josef S. Smolen, </li><li class="list-inline-item cited-by__entry__author">Peter Nash, </li><li class="list-inline-item cited-by__entry__author">Kevin Winthrop, </li><li class="list-inline-item cited-by__entry__author">Daniel Aletaha, </li><li class="list-inline-item cited-by__entry__author">Thomas Dörner, </li><li class="list-inline-item cited-by__entry__author">Roy Fleischmann, </li><li class="list-inline-item cited-by__entry__author">Yoshiya Tanaka, </li><li class="list-inline-item cited-by__entry__author">Jette Primdahl, </li><li class="list-inline-item cited-by__entry__author">Xenofon Baraliakos, </li><li class="list-inline-item cited-by__entry__author">Iain B. McInnes, </li><li class="list-inline-item cited-by__entry__author">Michael Trauner, </li><li class="list-inline-item cited-by__entry__author">Naveed Sattar, </li><li class="list-inline-item cited-by__entry__author">Maarten de Wit, </li><li class="list-inline-item cited-by__entry__author">Jan W. Schoones, </li><li class="list-inline-item cited-by__entry__author">Andreas Kerschbaumer, </li></ul><span class="cited-by__entry__title">Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement, </span><span class="cited-by__entry__series-title">Annals of the Rheumatic Diseases, </span><span class="cited-by__entry__volume"><strong>84</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(697-715), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ard.2025.01.024" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ard.2025.01.024</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ard.2025.01.024" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-13%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2022516%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022516" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2022516" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2022516.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2022516_f1.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/478506ca-9706-427f-9dc8-3e91b611d73c/assets/images/large/nejmoa2022516_f1.jpg" height="3438" width="1644" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">ACR20, ACR50, and ACR70 Responses over a Period of 24 Weeks.</div><div class="notes"><div role="doc-footnote">Patients were randomly assigned to receive oral upadacitinib at a dose of 15 mg or 30 mg once daily, placebo, or subcutaneous adalimumab at a dose of 40 mg every other week. Panel A shows the percentage of patients with at least 20% improvement in the American College of Rheumatology (ACR) response criteria (ACR20 response). P&lt;0.001 for the comparisons of the two upadacitinib doses with placebo with respect to the ACR20 response at 12 weeks (primary end point) and for the comparison of the 30-mg dose of upadacitinib with adalimumab. The noninferiority criterion was met for both upadacitinib doses as compared with adalimumab. Panel B shows the percentage of patients with at least 50% improvement in ACR response criteria (ACR50 response), and Panel C shows the percentage of patients with at least 70% improvement (ACR70 response). Missing data were imputed as nonresponse. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2022516_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2022516/asset/3db7b1ed-9f0a-4567-8e5b-b362649782a2/assets/images/large/nejmoa2022516_t1.jpg" height="2523" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">238 (55.5)</td><td class="xxxx-borders shading">236 (55.8)</td><td class="xxxx-borders shading">211 (49.9)</td><td class="xxxr-borders shading">222 (51.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age — yr</td><td class="xxxx-borders">51.6±12.2</td><td class="xxxx-borders">49.9±12.4</td><td class="xxxx-borders">50.4±12.2</td><td class="xxxr-borders">51.4±12.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">White race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">386 (90.0)</td><td class="xxxx-borders shading">377 (89.1)</td><td class="xxxx-borders shading">377 (89.1)</td><td class="xxxr-borders shading">375 (87.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Body-mass index ≥25 — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">342 (79.7)</td><td class="xxxx-borders">319 (75.4)</td><td class="xxxx-borders">329 (77.8)</td><td class="xxxr-borders">334 (77.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Duration of psoriatic arthritis — yr</td><td class="xxxx-borders shading">6.2±7.4</td><td class="xxxx-borders shading">5.9±6.4</td><td class="xxxx-borders shading">6.2±7.0</td><td class="xxxr-borders shading">5.9±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any nonbiologic DMARD at baseline — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">353 (82.3)</td><td class="xxxx-borders">346 (81.8)</td><td class="xxxx-borders">347 (82.0)</td><td class="xxxr-borders">347 (80.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Methotrexate alone</td><td class="xxxx-borders shading">279 (65.0)</td><td class="xxxx-borders shading">268 (63.4)</td><td class="xxxx-borders shading">267 (63.1)</td><td class="xxxr-borders shading">270 (62.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Methotrexate + another nonbiologic DMARD</td><td class="xxxx-borders">20 (4.7)</td><td class="xxxx-borders">27 (6.4)</td><td class="xxxx-borders">26 (6.1)</td><td class="xxxr-borders">16 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonbiologic DMARD other than methotrexate</td><td class="xxxx-borders shading">54 (12.6)</td><td class="xxxx-borders shading">51 (12.1)</td><td class="xxxx-borders shading">54 (12.8)</td><td class="xxxr-borders shading">61 (14.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Glucocorticoid use at baseline — no. (%)</td><td class="xxxx-borders">73 (17.0)</td><td class="xxxx-borders">71 (16.8)</td><td class="xxxx-borders">70 (16.5)</td><td class="xxxr-borders">72 (16.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Tender-joint count of 68 joints</td><td class="xxxx-borders shading">20.4±14.7</td><td class="xxxx-borders shading">19.4±13.3</td><td class="xxxx-borders shading">20.0±14.3</td><td class="xxxr-borders shading">20.1±13.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Swollen-joint count of 66 joints</td><td class="xxxx-borders">11.6±9.3</td><td class="xxxx-borders">10.6±7.1</td><td class="xxxx-borders">11.0±8.2</td><td class="xxxr-borders">11.6±8.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">High-sensitivity C-reactive protein &gt;ULN — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">324 (75.5)</td><td class="xxxx-borders shading">324 (76.6)</td><td class="xxxx-borders shading">324 (76.6)</td><td class="xxxr-borders shading">308 (71.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">HAQ-DI score<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">1.2±0.7</td><td class="xxxx-borders">1.1±0.6</td><td class="xxxx-borders">1.1±0.6</td><td class="xxxr-borders">1.1±0.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score for patient’s assessment of pain<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">6.2±2.1</td><td class="xxxx-borders shading">5.9±2.1</td><td class="xxxx-borders shading">6.1±2.1</td><td class="xxxr-borders shading">6.0±2.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Affected body-surface area ≥3% — no. (%)</td><td class="xxxx-borders">214 (49.9)</td><td class="xxxx-borders">210 (49.6)</td><td class="xxxx-borders">211 (49.9)</td><td class="xxxr-borders">211 (49.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">PASI score<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">9.8±10.0</td><td class="xxxx-borders shading">9.5±8.8</td><td class="xxxx-borders shading">11.2±11.4</td><td class="xxxr-borders shading">9.4±8.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on the sIGA of Psoriasis — no. (%)<a href="#core-t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">34 (7.9)</td><td class="xxxx-borders shading">21 (5.0)</td><td class="xxxx-borders shading">24 (5.7)</td><td class="xxxr-borders shading">34 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">73 (17.0)</td><td class="xxxx-borders">78 (18.4)</td><td class="xxxx-borders">86 (20.3)</td><td class="xxxr-borders">65 (15.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">2</td><td class="xxxx-borders shading">170 (39.6)</td><td class="xxxx-borders shading">173 (40.9)</td><td class="xxxx-borders shading">167 (39.5)</td><td class="xxxr-borders shading">181 (42.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">3</td><td class="xxxx-borders">133 (31.0)</td><td class="xxxx-borders">128 (30.3)</td><td class="xxxx-borders">119 (28.1)</td><td class="xxxr-borders">132 (30.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">4</td><td class="xxxx-borders shading">19 (4.4)</td><td class="xxxx-borders shading">23 (5.4)</td><td class="xxxx-borders shading">27 (6.4)</td><td class="xxxr-borders shading">17 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Presence of enthesitis — no. (%)<a href="#core-t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">270 (62.9)</td><td class="xxxx-borders">267 (63.1)</td><td class="xxxx-borders">241 (57.0)</td><td class="xxxr-borders">265 (61.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Presence of dactylitis — no. (%)<a href="#core-t1fn11" role="doc-noteref">¶¶</a></td><td class="xbxx-borders shading">136 (31.7)</td><td class="xbxx-borders shading">127 (30.0)</td><td class="xbxx-borders shading">126 (29.8)</td><td class="xbxr-borders shading">127 (29.6)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Upadacitinib at either dose was administered orally once daily, and adalimumab was administered subcutaneously at a dose of 40 mg every other week. DMARD denotes disease-modifying antirheumatic drug.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Permitted concomitant nonbiologic DMARDs included methotrexate, sulfasalazine, leflunomide, apremilast, hydroxychloroquine, bucillamine, and iguratimod.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The upper limit of the normal range (ULN) for C-reactive protein is 2.87 mg per liter.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Scores on the Health Assessment Questionnaire–Disability Index (HAQ-DI) range from 0 to 3, with higher scores indicating worse disability.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Scores for the patient’s assessment of pain were on a numerical rating scale from 0 to 10, with higher scores indicating greater severity of pain.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Shown is the score on the Psoriasis Area and Severity Index (PASI; range, 0 to 72, with higher scores indicating greater severity of psoriasis) among patients with an affected body-surface area of at least 3%.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">Scores on the Static Investigator Global Assessment (sIGA) of Psoriasis range from 0 to 4, with higher scores indicating more severe skin involvement.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t1fn10" role="paragraph" data-to-manipulate="true">The presence of enthesitis was defined by a score greater than 0 on the Leeds Enthesitis Index (range, 0 to 6, with higher scores indicating more affected sites).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="core-t1fn11" role="paragraph" data-to-manipulate="true">The presence of dactylitis was defined by a score greater than 0 on the Leeds Dactylitis Index (higher scores indicate more affected sites).</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2022516/asset/6aab9260-e4da-478d-a5d0-f0dac55f54ae/assets/images/large/nejmoa2022516_t2.jpg" height="3339" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Primary</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ACR20 response at wk 12 — no. (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">303 (70.6)</td><td class="xxxx-borders">332 (78.5)</td><td class="xxxx-borders">153 (36.2)</td><td class="xxxr-borders">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">34.5 (28.2 to 40.7); P&lt;0.001</td><td class="xxxx-borders">42.3 (36.3 to 48.3); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Secondary</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Least-squares mean change in HAQ-DI score at wk 12 (95% CI)</td><td class="xxxx-borders">−0.42 (−0.47 to −0.37) [404]</td><td class="xxxx-borders">−0.47 (−0.52 to −0.42) [398]</td><td class="xxxx-borders">−0.14 (−0.18 to −0.09) [392]</td><td class="xxxr-borders">−0.34 (−0.38 to −0.29) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders">−0.28 (−0.35 to −0.22); P&lt;0.001</td><td class="xxxx-borders">−0.34 (−0.40 to −0.27); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Score on the sIGA of Psoriasis of 0 or 1 and a decrease of ≥2 points from baseline at wk 16 — no./total no. (%) <a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">135/322 (41.9)</td><td class="xxxx-borders shading">175/324 (54.0)</td><td class="xxxx-borders shading">34/313 (10.9)</td><td class="xxxr-borders shading">127/330 (38.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders shading">31.1 (24.7 to 37.5); P&lt;0.001</td><td class="xxxx-borders shading">43.1 (36.7 to 49.6); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">PASI75 response at wk 16 — no./total no. (%) <a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">134/214 (62.6)</td><td class="xxxx-borders">131/210 (62.4)</td><td class="xxxx-borders">45/211 (21.3)</td><td class="xxxr-borders">112/211 (53.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">41.3 (32.8 to 49.8); P&lt;0.001</td><td class="xxxx-borders">41.1 (32.5 to 49.6); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in mTSS at wk 24 (95% CI)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">−0.04 (−0.16 to 0.07) [391]</td><td class="xxxx-borders shading">0.03 (−0.08 to 0.15) [383]</td><td class="xxxx-borders shading">0.25 (0.13 to 0.36) [372]</td><td class="xxxr-borders shading">0.01 (−0.11 to 0.13) [384]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">−0.29 (−0.44 to −0.14); P&lt;0.001</td><td class="xxxx-borders shading">−0.21 (−0.36 to −0.06); P=0.007</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Minimal disease activity at wk 24 — no. (%)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">157 (36.6)</td><td class="xxxx-borders">192 (45.4)</td><td class="xxxx-borders">52 (12.3)</td><td class="xxxr-borders">143 (33.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">24.3 (18.8 to 29.8); P&lt;0.001</td><td class="xxxx-borders">33.1 (27.4 to 38.8); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Resolution of enthesitis at wk 24 — no./total no. (%)<a href="#core-t2fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">145/270 (53.7)</td><td class="xxxx-borders shading">154/267 (57.7)</td><td class="xxxx-borders shading">78/241 (32.4)</td><td class="xxxr-borders shading">125/265 (47.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders shading">21.3 (13.0 to 29.7); P&lt;0.001</td><td class="xxxx-borders shading">25.3 (16.9 to 33.7); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ACR20 response at wk 12: noninferiority of upadacitinib to adalimumab — no. (%)</td><td class="xxxx-borders">303 (70.6)</td><td class="xxxx-borders">332 (78.5)</td><td class="xxxx-borders">153 (36.2)</td><td class="xxxr-borders">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percentage of adalimumab effect preserved (95% CI)<a href="#core-t2fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">119.4 (98.0 to 147.9); P&lt;0.001</td><td class="xxxx-borders">146.6 (122.8 to 180.4); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in SF-36 PCS score at wk 12 (95% CI)<a href="#core-t2fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">7.9 (7.1 to 8.6) [405]</td><td class="xxxx-borders shading">8.9 (8.1 to 9.7) [398]</td><td class="xxxx-borders shading">3.2 (2.4 to 4.0) [394]</td><td class="xxxr-borders shading">6.8 (6.1 to 7.6) [410]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">4.7 (3.7 to 5.7); P&lt;0.001</td><td class="xxxx-borders shading">5.7 (4.7 to 6.7); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Least-squares mean change in FACIT-Fatigue score (95% CI)<a href="#core-t2fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">6.3 (5.4 to 7.2) [404]</td><td class="xxxx-borders">7.1 (6.2 to 8.0) [398]</td><td class="xxxx-borders">2.8 (1.9 to 3.7) [394]</td><td class="xxxr-borders">5.7 (4.8 to 6.6) [410]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xxxx-borders">3.5 (2.4 to 4.7); P&lt;0.001</td><td class="xxxx-borders">4.3 (3.1 to 5.5); P&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">ACR20 response at wk 12: superiority of upadacitinib to adalimumab — no. (%)</td><td class="xxxx-borders shading">303 (70.6)</td><td class="xxxx-borders shading">332 (78.5)</td><td class="xxxx-borders shading">153 (36.2)</td><td class="xxxr-borders shading">279 (65.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. adalimumab — percentage points (95% CI)</td><td class="xxxx-borders shading">5.6 (−0.6 to 11.8)<a href="#core-t2fn11" role="doc-noteref">¶¶</a></td><td class="xxxx-borders shading">13.5 (7.5 to 19.4); P&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Resolution of dactylitis at wk 24 — no./total no. (%)<a href="#core-t2fn12" role="doc-noteref">‖‖</a></td><td class="xxxx-borders">104/136 (76.5)</td><td class="xxxx-borders">101/127 (79.5)</td><td class="xxxx-borders">50/126 (39.7)</td><td class="xxxr-borders">94/127 (74.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo — percentage points (95% CI)</td><td class="xxxx-borders">36.8 (25.7 to 47.9)</td><td class="xxxx-borders">39.8 (28.8 to 50.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in patient’s assessment of pain at wk 12: superiority of upadacitinib to adalimumab (95% CI)<a href="#core-t2fn13" role="doc-noteref">***</a></td><td class="xxxx-borders shading">−2.3 (−2.5 to −2.0) [404]</td><td class="xxxx-borders shading">−2.7 (−2.9 to −2.5) [398]</td><td class="xxxx-borders shading">−0.9 (−1.2 to −0.7) [392]</td><td class="xxxr-borders shading">−2.3 (−2.5 to −2.1) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. adalimumab (95% CI)</td><td class="xxxx-borders shading">0.0 (−0.3 to 0.3)</td><td class="xxxx-borders shading">−0.5 (−0.7 to −0.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change in HAQ-DI score at wk 12: superiority of upadacitinib to adalimumab</td><td class="xxxx-borders">−0.42 (−0.47 to −0.37) [404]</td><td class="xxxx-borders">−0.47 (−0.52 to −0.42) [398]</td><td class="xxxx-borders">−0.14 (−0.18 to −0.09) [392]</td><td class="xxxr-borders">−0.34 (−0.38 to −0.29) [406]</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Least-squares mean difference vs. adalimumab (95% CI)</td><td class="xxxx-borders">−0.08 (−0.15 to −0.01)</td><td class="xxxx-borders">−0.14 (−0.20 to −0.07)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Least-squares mean change in Self-Assessment of Psoriasis Symptoms score at wk 16 — (95% CI)<a href="#core-t2fn14" role="doc-noteref">†††</a></td><td class="xxxx-borders shading">−25.3 (−27.3 to −23.4) [396]</td><td class="xxxx-borders shading">−28.1 (−30.0 to −26.1) [395]</td><td class="xxxx-borders shading">−8.2 (−10.2 to −6.3) [388]</td><td class="xxxr-borders shading">−22.7 (−24.7 to −20.8) [407]</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Least-squares mean difference vs. placebo (95% CI)</td><td class="xbxx-borders shading">−17.1 (−19.6 to −14.6)</td><td class="xbxx-borders shading">−19.8 (−22.3 to −17.3)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The primary and secondary efficacy end points were subject to a graphical testing procedure to control for the global type I error. For continuous end points, the number of patients with available data is shown in brackets.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Patients with an American College of Rheumatology 20 (ACR20) response had a decrease from baseline of at least 20% in the number of tender and swollen joints and an improvement of at least 20% in at least three of five other domains.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Results were assessed in patients with baseline score of at least 2.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">A PASI75 response indicates a decrease of at least 75% from baseline in the PASI score. Results were assessed in patients with an affected body-surface area of at least 3% at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Values for the modified total Sharp–van der Heijde Score (mTSS) range from 0 to 528, with higher scores indicating greater damage.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Minimal disease activity was determined by fulfilling five of seven criteria: a tender-joint count of 0 or 1; a swollen-joint count of 0 or 1; a PASI score of 0 or 1 or an affected body-surface area of 3% or less; a score on the patient assessment of pain of 1.5 or less (range, 0 to 10, with higher scores indicating more pain); a score on the patient’s global assessment of disease activity of 2 or less (range, 0 to 10, with higher scores indicating more disease activity); a HAQ-DI score of 0.5 or less; and a score on the Leeds Enthesitis Index of 0 or 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t2fn7" role="paragraph" data-to-manipulate="true">Resolution of enthesitis was defined by a score of 0 on the Leeds Enthesitis Index. Results were assessed in patients with a baseline score greater than 0.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t2fn8" role="paragraph" data-to-manipulate="true">The percentage of adalimumab effect preserved was based on Koch’s three-group noninferiority approach and calculated as [(upadacitinib−placebo) ÷ (adalimumab−placebo)×100%].</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t2fn9" role="paragraph" data-to-manipulate="true">Norm-based scores were used for the score on the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS), with higher scores indicating better health-related quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t2fn10" role="paragraph" data-to-manipulate="true">Scores on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) range from 0 to 52, with higher scores indicating less fatigue.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶¶</div><div id="core-t2fn11" role="paragraph" data-to-manipulate="true">For the secondary end points, hierarchical testing failed at the end point of “ACR20 response at week 12: superiority of upadacitinib to adalimumab” in the comparison of the 15-mg dose of upadacitinib with adalimumab.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖‖</div><div id="core-t2fn12" role="paragraph" data-to-manipulate="true">Resolution of dactylitis was defined by a score of 0 on the Leeds Dactylitis Index. Results were assessed in patients with a baseline score greater than 0.</div></div><div role="doc-footnote" data-has="label"><div class="label">***</div><div id="core-t2fn13" role="paragraph" data-to-manipulate="true">The patient’s assessment of pain was determined on the same scale as in the criterion for minimal disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">†††</div><div id="core-t2fn14" role="paragraph" data-to-manipulate="true">Scores on the Self-Assessment of Psoriasis Symptoms range from 0 to 110, with higher scores indicating greater severity of symptoms.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Secondary End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2022516/asset/a44e22a3-e9fe-475e-a7f2-d71d12587e19/assets/images/large/nejmoa2022516_t3.jpg" height="2871" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event or Variable</th><th class="txxx-borders">Upadacitinib, 15 mg<br>(N=429)</th><th class="txxx-borders">Upadacitinib, 30 mg<br>(N=423)</th><th class="txxx-borders">Placebo<br>(N=423)</th><th class="txxr-borders">Adalimumab<br>(N=429)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patients with adverse events — no. (%)</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">287 (66.9)</td><td class="xxxx-borders">306 (72.3)</td><td class="xxxx-borders">252 (59.6)</td><td class="xxxr-borders">278 (64.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">14 (3.3)</td><td class="xxxx-borders shading">26 (6.1)</td><td class="xxxx-borders shading">13 (3.1)</td><td class="xxxr-borders shading">16 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of placebo, upadacitinib, or adalimumab</td><td class="xxxx-borders">13 (3.0)</td><td class="xxxx-borders">21 (5.0)</td><td class="xxxx-borders">13 (3.1)</td><td class="xxxr-borders">22 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Infection</td><td class="xxxx-borders">169 (39.4)</td><td class="xxxx-borders">183 (43.3)</td><td class="xxxx-borders">140 (33.1)</td><td class="xxxr-borders">146 (34.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">11 (2.6)</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxr-borders shading">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Opportunistic</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">2 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Herpes zoster<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">3 (0.7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Active tuberculosis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hepatic disorder</td><td class="xxxx-borders shading">39 (9.1)</td><td class="xxxx-borders shading">52 (12.3)</td><td class="xxxx-borders shading">16 (3.8)</td><td class="xxxr-borders shading">67 (15.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Cancer<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonmelanoma skin cancer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.5)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cancer other than nonmelanoma skin cancer</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Lymphoma</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Anemia</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxx-borders">20 (4.7)</td><td class="xxxx-borders">4 (0.9)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neutropenia</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">21 (5.0)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">10 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">6 (1.4)</td><td class="xxxx-borders">15 (3.5)</td><td class="xxxx-borders">5 (1.2)</td><td class="xxxr-borders">1 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Elevated creatine kinase level</td><td class="xxxx-borders shading">38 (8.9)</td><td class="xxxx-borders shading">41 (9.7)</td><td class="xxxx-borders shading">6 (1.4)</td><td class="xxxr-borders shading">24 (5.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Renal dysfunction</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major adverse cardiovascular event<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxr-borders shading">2 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Venous thromboembolism<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxr-borders">2 (0.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Least-squares mean change in laboratory measures from baseline to wk 24</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Hemoglobin — g/dl</td><td class="xxxx-borders">−0.7±9.8</td><td class="xxxx-borders">−2.7±9.6</td><td class="xxxx-borders">0.0±7.7</td><td class="xxxr-borders">2.7±9.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neutrophils — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders shading">−0.515±1.939</td><td class="xxxx-borders shading">−0.834±1.856</td><td class="xxxx-borders shading">0.052±1.659</td><td class="xxxr-borders shading">−1.015±1.695</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Lymphocytes — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders">0.064±0.527</td><td class="xxxx-borders">0.143±0.604</td><td class="xxxx-borders">0.095±0.419</td><td class="xxxr-borders">0.443±0.575</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Platelets — ×10<sup>−9</sup>/liter</td><td class="xxxx-borders shading">−2.1±57.7</td><td class="xxxx-borders shading">6.7±58.7</td><td class="xxxx-borders shading">−4.7±55.4</td><td class="xxxr-borders shading">−20.3±50.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">LDL cholesterol — mmol/liter</td><td class="xxxx-borders">0.408±0.790</td><td class="xxxx-borders">0.447±0.809</td><td class="xxxx-borders">0.025±0.619</td><td class="xxxr-borders">0.034±0.634</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">HDL cholesterol — mmol/liter</td><td class="xxxx-borders shading">0.223±0.270</td><td class="xxxx-borders shading">0.249±0.294</td><td class="xxxx-borders shading">0.003±0.230</td><td class="xxxr-borders shading">0.080±0.270</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">ALT — U/liter</td><td class="xxxx-borders">6.1±20.7</td><td class="xxxx-borders">7.9±23.4</td><td class="xxxx-borders">−1.0±16.9</td><td class="xxxr-borders">5.0±19.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">AST — U/liter</td><td class="xxxx-borders shading">5.7±13.8</td><td class="xxxx-borders shading">7.1±12.5</td><td class="xxxx-borders shading">−1.1±15.3</td><td class="xxxr-borders shading">2.9±13.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Creatinine — μmol/liter</td><td class="xxxx-borders">4.7±10.1</td><td class="xxxx-borders">6.3±8.8</td><td class="xxxx-borders">1.6±8.8</td><td class="xxxr-borders">4.1±39.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Creatine kinase — U/liter</td><td class="xbxx-borders shading">85.2±110.8</td><td class="xbxx-borders shading">140.0±342.8</td><td class="xbxx-borders shading">20.0±331.3</td><td class="xbxr-borders shading">25.8±105.3</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Plus–values are means ±SD. Adverse events were coded according to the <i>Medical Dictionary for Regulatory Activities</i>. Laboratory data were graded with the use of the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.03. Changes in laboratory variables are reported on the basis of single measurements. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for creatinine to milligrams per deciliter, divide by 88.4. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, HDL high-density lipoprotein, and LDL low-density lipoprotein.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">All cases of herpes zoster were nonserious and mild or moderate in severity, without ophthalmic, central nervous system, or other internal organ involvement.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">In the placebo group, one patient had basal-cell carcinoma. In the 15-mg upadacitinib group, one patient had neuroendocrine carcinoma. In the 30-mg upadacitinib group, two patients had basal-cell carcinoma and one had a malignant lung neoplasm. In the adalimumab group, one patient each had colon cancer, ovarian cancer, and uterine cancer.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Major adverse cardiovascular events were defined as nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes and were adjudicated by an independent committee whose members were unaware of the trial group assignments.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">Venous thromboembolism was defined as deep-vein thrombosis or pulmonary embolism. Cases were adjudicated by an independent committee whose members were unaware of the trial group assignments.</div></div></div></figcaption></a><figcaption><div class="caption">Safety Summary through Week 24.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2022516_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2022516</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. <em>Lancet</em> 2018;391:2503-2512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31115-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29908669/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436403700024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+upadacitinib+in+patients+with+rheumatoid+arthritis+and+inadequate+response+to+conventional+synthetic+disease-modifying+anti-rheumatic+drugs+%28SELECT-NEXT%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2503-2512&amp;doi=10.1016%2FS0140-6736%2818%2931115-2&amp;pmid=29908669" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. <em>Arthritis Rheumatol</em> 2019;71:1788-1800.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31287230/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Upadacitinib+versus+placebo+or+adalimumab+in+patients+with+rheumatoid+arthritis+and+an+inadequate+response+to+methotrexate%3A+results+of+a+phase+III%2C+double-blind%2C+randomized+controlled+trial.&amp;publication_year=2019&amp;journal=Arthritis+Rheumatol&amp;pages=1788-1800&amp;doi=10.1002%2Fart.41032&amp;pmid=31287230" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <em>Lancet</em> 2018;391:2513-2524.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)31116-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29908670/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436403700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+upadacitinib+in+patients+with+active+rheumatoid+arthritis+refractory+to+biologic+disease-modifying+anti-rheumatic+drugs+%28SELECT-BEYOND%29%3A+a+double-blind%2C+randomised+controlled+phase+3+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=2513-2524&amp;doi=10.1016%2FS0140-6736%2818%2931116-4&amp;pmid=29908670" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <em>Lancet</em> 2019;393:2303-2311.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)30419-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31130260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000470263400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Upadacitinib+as+monotherapy+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+%28SELECT-MONOTHERAPY%29%3A+a+randomised%2C+placebo-controlled%2C+double-blind+phase+3+study.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2303-2311&amp;doi=10.1016%2FS0140-6736%2819%2930419-2&amp;pmid=31130260" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. <em>Arthritis Rheumatol</em> 2020 July 8 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41384" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32638504/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+upadacitinib+monotherapy+in+methotrexate-na%C3%AFve+patients+with+moderately+to+severely+active+rheumatoid+arthritis+%28SELECT-EARLY%29%3A+a+randomized%2C+double-blind%2C+active-comparator%2C+multi-center%2C+multi-country+trial.&amp;publication_year=2020&amp;journal=Arthritis+Rheumatol&amp;doi=10.1002%2Fart.41384&amp;pmid=32638504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for the treatment of rheumatoid arthritis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for these two diseases cannot be made. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <em>Arthritis Rheum</em> 2006;54:2665-2673.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.21972" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16871531/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239641400037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Classification+criteria+for+psoriatic+arthritis%3A+development+of+new+criteria+from+a+large+international+study.&amp;publication_year=2006&amp;journal=Arthritis+Rheum&amp;pages=2665-2673&amp;doi=10.1002%2Fart.21972&amp;pmid=16871531" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. <em>J Rheumatol</em> 1982;9:789-793.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7175852/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PQ06200032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+dimensions+of+health+outcomes%3A+the+health+assessment+questionnaire%2C+disability+and+pain+scales.&amp;publication_year=1982&amp;journal=J+Rheumatol&amp;pages=789-793&amp;pmid=7175852" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. <em>J Dermatolog Treat</em> 2015;26:23-31.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/09546634.2013.865009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24354461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350751100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+5-point+Investigator%E2%80%99s+Global+Assessment+%28IGA%29+Scale%3A+a+modified+tool+for+evaluating+plaque+psoriasis+severity+in+clinical+trials.&amp;publication_year=2015&amp;journal=J+Dermatolog+Treat&amp;pages=23-31&amp;doi=10.3109%2F09546634.2013.865009&amp;pmid=24354461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. <em>Dermatologica</em> 1978;157:238-244.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000250839" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/357213/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1978FJ96400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Severe+psoriasis+%E2%80%94+oral+therapy+with+a+new+retinoid.&amp;publication_year=1978&amp;journal=Dermatologica&amp;pages=238-244&amp;doi=10.1159%2F000250839&amp;pmid=357213" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. <em>Ann Rheum Dis</em> 2010;69:48-53.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/ard.2008.102053" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19147615/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272594100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+minimal+disease+activity+in+psoriatic+arthritis%3A+a+proposed+objective+target+for+treatment.&amp;publication_year=2010&amp;journal=Ann+Rheum+Dis&amp;pages=48-53&amp;doi=10.1136%2Fard.2008.102053&amp;pmid=19147615" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. <em>Arthritis Rheum</em> 2008;59:686-691.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.23568" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18438903/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255848000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measuring+clinical+enthesitis+in+psoriatic+arthritis%3A+assessment+of+existing+measures+and+development+of+an+instrument+specific+to+psoriatic+arthritis.&amp;publication_year=2008&amp;journal=Arthritis+Rheum&amp;pages=686-691&amp;doi=10.1002%2Fart.23568&amp;pmid=18438903" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: Quality Metric, 2000.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Ware+JE%2C+Kosinski+M%2C+Dewey+JE.+How+to+score+version+two+of+the+SF-36+health+survey.+Lincoln%2C+RI%3A+Quality+Metric%2C+2000." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Cella D, Lai J-S, Chang C-H, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. <em>Cancer</em> 2002;94:528-538.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.10245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11900238/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000173303800031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fatigue+in+cancer+patients+compared+with+fatigue+in+the+general+United+States+population.&amp;publication_year=2002&amp;journal=Cancer&amp;pages=528-538&amp;doi=10.1002%2Fcncr.10245&amp;pmid=11900238" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. <em>J Rheumatol</em> 2005;32:1745-1750.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16142872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000231921300021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+an+assessment+tool+for+dactylitis+in+patients+with+psoriatic+arthritis.&amp;publication_year=2005&amp;journal=J+Rheumatol&amp;pages=1745-1750&amp;pmid=16142872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Armstrong AW, Banderas B, Foley C, Stokes J, Sundaram M, Shields AL. Development and psychometric evaluation of the Self-Assessment of Psoriasis Symptoms (SAPS)–Clinical Trial and the SAPS–Real World patient-reported outcomes. <em>J Dermatolog Treat</em> 2017;28:505-514.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/09546634.2017.1290206" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28147886/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412796100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+and+psychometric+evaluation+of+the+Self-Assessment+of+Psoriasis+Symptoms+%28SAPS%29%E2%80%93Clinical+Trial+and+the+SAPS%E2%80%93Real+World+patient-reported+outcomes.&amp;publication_year=2017&amp;journal=J+Dermatolog+Treat&amp;pages=505-514&amp;doi=10.1080%2F09546634.2017.1290206&amp;pmid=28147886" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/722852/director-consultation-liaison-psychiatrist-staten-island-ny/?query=fjwp&amp;rid=3059">Director, Consultation-Liaison Psychiatrist - Staten Island, NY</a></div></div><div class="nejm-widget_item"><div><span> Hampstead, New Hampshire</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877603/child-and-adolescent-psychiatrist/?query=fjwp&amp;rid=217510">Child and Adolescent Psychiatrist</a></div></div><div class="nejm-widget_item"><div><span> Mountain View, California</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889135/physician-obstetrics-gynecology-mountain-view-ca-/?query=fjwf&amp;rid=845671">Physician, Obstetrics-Gynecology (Mountain View, CA)</a></div></div><div class="nejm-widget_item"><div><span> Bloomington, Indiana</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886385/top-ranked-iu-health-neonatology-in-bloomington-indiana/?query=fjwf&amp;rid=17394">Top-Ranked IU Health Neonatology in Bloomington, Indiana</a></div></div><div class="nejm-widget_item"><div><span> Vancouver, Washington State</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877072/family-medicine-physician/?query=fjwf&amp;rid=14710">Family Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880496/neurologist-autonomic-disorders-specialist/?query=fjwf&amp;rid=2201">Neurologist - Autonomic Disorders Specialist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2022516&amp;pubId=41289757&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6763b1396f211-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6763b1396f211-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6763b1396f211-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$842282364$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$842282364$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$842282364$--></div></div><div class="mlt-body"><!--?lit$842282364$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$842282364$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$842282364$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$842282364$-->May 29, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2413449?query=recirc_Semantic" target="_self">A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis</a></div><div class="mlt-article-authors"><!--?lit$842282364$-->D. Blockmans and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$842282364$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$842282364$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$842282364$-->May 25, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212728?query=recirc_Semantic" target="_self">Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease</a></div><div class="mlt-article-authors"><!--?lit$842282364$-->E.V. Loftus, Jr., and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$842282364$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$842282364$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$842282364$-->May 29, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2503584?query=recirc_Semantic" target="_self">Upadacitinib — An Up-and-Comer for Treatment of Giant-Cell Arteritis</a></div><div class="mlt-article-authors"><!--?lit$842282364$-->M.J. Koster and K.J. Warrington</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$842282364$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$842282364$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$842282364$-->Jul 08, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2102388?query=recirc_Semantic" target="_self">Bimekizumab versus Adalimumab in Plaque Psoriasis</a></div><div class="mlt-article-authors"><!--?lit$842282364$-->R.B. Warren and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$842282364$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$842282364$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$842282364$-->Oct 15, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2008250?query=recirc_Semantic" target="_self">Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis</a></div><div class="mlt-article-authors"><!--?lit$842282364$-->A. Rubbert-Roth and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2022516?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2022516" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2022516.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2022516"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2021712" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2024670" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2022516_f1.jpg"><img src="/cms/10.1056/NEJMoa2022516/asset/478506ca-9706-427f-9dc8-3e91b611d73c/assets/images/large/nejmoa2022516_f1.jpg" height="3438" width="1644" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">ACR20, ACR50, and ACR70 Responses over a Period of 24 Weeks.</div><div class="notes"><div role="doc-footnote">Patients were randomly assigned to receive oral upadacitinib at a dose of 15 mg or 30 mg once daily, placebo, or subcutaneous adalimumab at a dose of 40 mg every other week. Panel A shows the percentage of patients with at least 20% improvement in the American College of Rheumatology (ACR) response criteria (ACR20 response). P&lt;0.001 for the comparisons of the two upadacitinib doses with placebo with respect to the ACR20 response at 12 weeks (primary end point) and for the comparison of the 30-mg dose of upadacitinib with adalimumab. The noninferiority criterion was met for both upadacitinib doses as compared with adalimumab. Panel B shows the percentage of patients with at least 50% improvement in ACR response criteria (ACR50 response), and Panel C shows the percentage of patients with at least 70% improvement (ACR70 response). Missing data were imputed as nonresponse. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Safety Summary through Week 24.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/13" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 13</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2032125" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.J. Kelly and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2024670" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Mbala-Kingebeni and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Apr 01, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2024277" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Sotatercept for the Treatment of Pulmonary Arterial Hypertension</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Humbert and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2022516%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2022516&amp;pubId=41289757&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2022516%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2022516&amp;pubId=41289757&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id004499983912457772" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6763b1396f211-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6763b1396f211-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6763b1396f211-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6763b1396f211-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6763b1396f211-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6763b1396f211-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6763b1396f211-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6763b1396f211-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6763b1396f211-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6763b1396f211-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6763b0c4ff211',t:'MTc0OTUzMzI3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6763b0c4ff211&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><pix-nptdocqlicqz></pix-nptdocqlicqz><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2022516?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-transactionid="waz7315mg780f34in307sdyqlal2c31crqa7hn1h" id="captureIFrame_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="waz7315mg780f34in307sdyqlal2c31crqa7hn1h" target="captureIFrame_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="capture_screen"><input id="capture_signIn_js_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="js_version"><input id="capture_signIn_transactionId_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="waz7315mg780f34in307sdyqlal2c31crqa7hn1h" type="hidden" class="capture_transactionId_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="capture_transactionId"><input id="capture_signIn_form_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="form"><input id="capture_signIn_flow_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="flow"><input id="capture_signIn_client_id_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="client_id"><input id="capture_signIn_redirect_uri_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="redirect_uri"><input id="capture_signIn_response_type_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="response_type"><input id="capture_signIn_flow_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="flow_version"><input id="capture_signIn_settings_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="settings_version"><input id="capture_signIn_locale_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="locale"><input id="capture_signIn_recaptcha_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_waz7315mg780f34in307sdyqlal2c31crqa7hn1h" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>